Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

CONFIDENTIAL TREATMENT REQUEST  

  
 

    EXHIBIT 10.37    
  

*    Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 
 

HS-HET
  STRATEGIC AGREEMENT    
  

        This Strategic Agreement ("this Agreement") is made and entered into as of this 23rd day of May,
2002 ("Effective Date"), by and between HealtheTech, Inc, a Delaware corporation having its principal place of business at 523 Park Point Drive, Third
Floor, Golden, Colorado 80401 USA ("HET"), and HEALTHSOUTH Corporation, located at One Healthsouth Parkway, Birmingham, Alabama 35243
("HS"). 

Recitals  

        Whereas, HET is a personal health monitoring company that develops, manufactures, and markets various devices,
software, and services for consumer health, fitness, and nutrition. 

        Whereas, HS is the world's leader in outpatient rehabilitative healthcare services and outpatient surgery and diagnostics through a
nation-wide network of facilities. 

        Whereas, HS wishes to purchase certain HET products for use in HS's facilities subject to the terms and conditions of this Agreement. 

        Whereas, HET wishes to appoint HS as an authorized exclusive distributor of certain HET products in the markets, and HS wishes to accept
this appointment, subject to the terms and conditions of this Agreement. 

        Whereas, HET wishes to appoint HS as an authorized exclusive provider of certain Wellness Services using HET Products (as hereinafter
defined), and HS wishes to accept this appointment, subject to the terms and conditions of this Agreement. 

Agreement  

        Accordingly, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows: 

	1.
	DEFINITIONS. In this Agreement, unless the context otherwise requires, capitalized terms shall have the following respective meanings: 

"Affiliate" means, with respect to a party, any person or entity that controls, is controlled by, or is under common control with such party, where
"control" means ownership of fifty percent (50%) or more of the outstanding voting securities (but only as long as such person or entity meets these requirements). 

"BodyGem" means the BodyGemTM metabolic measurement device manufactured by HET. BodyGem is a handheld, portable indirect calorimeter intended
for use in non-clinical applications to measure and display RMR, the number of calories a person burns per day at rest. 

"End User" means a person, company, or other legal entity that purchases a Product for its own internal purposes and not for distribution to, or use on
behalf of, others. 

1

 

"Excluded Accounts" shall be each of the customers and potential customers set forth on Schedule I, in each case limited to locations that are
current customers of HET or those that HET is in active discussions with. 

"HET Marks" means the worldwide copyrights, trade secrets, patents, patent applications, trademarks, service marks, and any other intellectual property
rights and trade names of HET listed in Exhibit C (as such list may be updated from time to time by HET upon notice to HS). 

"Markets" means the facilities and channels specifically identified in Section 2.1. 

"MedGem" means the MedGemTM metabolic measurement device manufactured by HET. The MedGem has received clearance from the FDA.
MedGemTM is a handheld, portable indirect calorimeter intended for use in clinical and research applications to measure oxygen uptake. The MedGem device accurately measures respiratory
airflow and oxygen uptake (also referred to as oxygen consumption, VO2) and determines resting metabolic rate (RMR), the number of calories a person burns per day at rest. 

"Period" is defined in Exhibit B. 

"Products" means only those devices and software of HET that are specifically listed in  Exhibit A. HET may change the specifications, components, design,
performance and appearance of any Product at any time. HET will give HS written
notice of any such change, whereupon Exhibit Awill be amended to reflect the change. 

"Purchase Commitments" means the purchase commitments established by the parties in accordance with this Agreement. The Purchase Commitments for the
Term are set forth in Exhibit B. 

"Single Use Breathing Insert" means the "disposable" facemask or mouthpiece that an individual breathes into during a BodyGem or MedGem metabolic
measurement. 

"Software Products" means BalanceLogTM, MedGem AnalyzerTM, GlucoPilotTM and BodyGem AnalyzerTM. 

"Term" is defined in Section 10.1 (Term). 

"User Documentation" means the user documentation and instruction manuals furnished to HS by HET for distribution along with the Products. 

"Wellness Services" means the providing of resting metabolic rate measurements using the MedGem in medical applications under the direction of a
physician and the BodyGem in non-medical applications. 

	2.
	RELATIONSHIP OF THE PARTIES.

	2.1
	Exclusivity. Subject to HS fulfilling the purchase commitments of Section 3.1(b), hereinafter, HET hereby grants HS, for the
term of the Agreement, in the United States of America, except to those accounts listed in Schedule I:

	(a)
	the
exclusive right to purchase and use products within HS facilities;

	(b)
	the
exclusive right to purchase for use in, and resell BodyGems to the following, freestanding, non-hospital End Users: outpatient rehabilitation facilities, physical
therapy facilities, sports medicine facilities, independent fitness facilities (those representing 5 or fewer affiliated centers), and diagnostic imaging facilities; and

	(c)
	the
exclusive right to provide Wellness Services to:

	(i)
	corporate
in-house wellness programs 

2

 

	(ii)
	fitness
facilities

	(iii)
	professional
athletic teams and University and High School athletic programs

	(iv)
	pharmacies

	(v)
	GNC
facilities 

	(d)
	the
non-exclusive right to resell Software Products within HS operated facilities. 

HET
may sell Products and provide Wellness Services to any entity to which HS is unable or unwilling to sell Products or Wellness Services upon sixty (60) days written notice to HS. 

	2.2
	Independent Contractor. HS is an independent contractor and not an agent, employee, franchisee or partner of HET, and is acting in the
ordinary course of business. HS does not have any authority to, and will not create or assume any obligation, express or implied, on behalf of HET. HS shall be responsible for all taxes and payments
concerning HS, its employees and its sales representatives. This Agreement does not create or evidence any joint venture or partnership of the parties. 

	3.
	OBLIGATIONS OF THE PARTIES.

	3.1
	Obligations of HS. HS will:

	(a)
	Develop Sales. Use commercially reasonable efforts to aggressively develop sales of the Products and Wellness Services in its areas of
exclusivity. In furtherance thereof, HS will fulfill the obligations defined in Exhibit E. 

(b)     (i)    Purchase Commitments. Upon execution of this Agreement, HS will give HET a purchase order for
[*] MedGems and [*] disposables per MedGem with the initial [*] MedGem units and disposables to be delivered by June 1,
2002 and the remaining MedGem units to be delivered by August 31, 2002. HS will further use commercially reasonable efforts to achieve, in each Period indicated in  Exhibit B, at least the
Purchase Commitment for such Period. The Purchase Commitment shall be calculated as set forth in such exhibit. HS hereby
acknowledges the Purchase Commitments are reasonable and constitute a material obligation herein. 

	(ii)
	If
HS fails to purchase from HET within thirty (30) days after the end of any Period the amount of Products (calculated based on the amount paid to HET) indicated in  Exhibit B for such Period,
then the exclusivity rights granted to HS's under Section 2.1
shall thereupon terminate. If in the third or any succeeding Period HS exceeds the Purchase Commitment for such Period, such excess may reduce the Purchase Commitment for the next succeeding Period. 

	3.2
	Obligations of HET. HET will:

	(a)
	Refer Inquiries. Refer to HS all inquiries for purchase of Products received from the Markets in which HS has an exclusive right to
sell to such opportunity;

	(b)
	Notice of Product Problems. Promptly inform HS of any Product complaints or adverse reactions that are, in HET's reasonable judgment,
significant, and of all matters that are, in HET's reasonable judgment, important concerning the quality and performance of Products;

	(c)
	Provide Technical Support. As more fully set forth in Exhibit E, provide
technical specifications and other information required to support HS's securing of registrations, permits, licenses, approvals and other governmental actions required to handle, market, sell,
demonstrate, use or distribute Products in the Markets; and 

3

 

	(d)
	Right of First Negotiation. Provide to HS the right of first negotiation to add new health monitoring devices offered by HET to the
list of Products provided in Exhibit A. This right of first negotiation shall consist of HET notifying HS of the projected availability of a new
product and its associated proposed pricing, and providing HS sixty (60) days following delivery of a prototype to HS to evaluate and exclusively negotiate with HET pricing and Purchase
Commitments associated with the new product. If HS elects not to include the new product in the list of Products, or if the parties are unable to come to a mutual agreement on the pricing and Purchase
Commitments associated with the new product terms within that sixty (60) day period, HET shall have the right to negotiate with other parties for distribution rights for that product in the
Markets.

	(e)
	Domestic
Aftermarket Support. Healthetech shall comply with the necessary Food and Drug Administration (FDA) 510(k) regulations to assure the MedGemTM maintains
market clearance. Healthetech shall comply with all regulatory tracking and monitoring requirements for all medical devices sold or otherwise transferred to HS for sale or distribution as required by
FDA 21 CFR § 820 and the Medical Device Reporting Regulation. Healthetech shall investigate, collect and report data to regulatory agencies as required by those agencies. 

	3.3
	Forecasts. Beginning in October 2002, at least fifteen (15) days before the beginning of each month, HS will furnish HET
with a rolling forecast, by month, of Product sales by units for each Product for the next succeeding twelve months accompanied by a binding purchase order for the third succeeding month.
Forecasts are not binding on HS. However, HS acknowledges that compliance with this provision is a material obligation herein. 

	4.
	PURCHASE AND SALE OF PRODUCTS.

	4.1
	Orders. HS's orders for Products are subject to acceptance by HET and to the provisions of this Agreement. HS shall submit a written
purchase order to HET for each order and HET shall transmit a written or verbal (telephone call) order confirmation within five (5) business days from receipt of the purchase order
confirming the Product quantities to be shipped and the estimated shipping date. HS shall use reasonable efforts to order all Products equally over each calendar quarter. Once a purchase order is
accepted, HET will fill and ship orders in accordance with its customary procedures subject to Product availability. HET may allocate its output according to its sole judgment if demand exceeds its
manufacturing capacity. HET may choose the mode of shipment and carrier unless otherwise specified in the order.

	4.2
	Delivery. HET will deliver all Products sold to HS F.O.B. HET's warehouse in San Jose, CA or other location to be agreed upon.
Title to and all risk of loss of or damage or casualty to such Products will pass to HS upon delivery to the carrier. If Product is not shipped freight collect, HS will reimburse HET on demand
for all shipping charges, premiums for freight insurance, and transportation costs incurred by HET. HET may, at its option, select the freight forwarder

	4.3
	Limited Acceptance Remedy. If, on delivery, all or any part of a Product is nonconforming, then HS's sole remedy shall be to exchange
such Product with another, conforming Product unit or, at HET's option, upon return of such Product receive a refund of all amounts paid to HET for such nonconforming Product. Such remedies shall be
HS's sole and exclusive remedies if HET delivers a nonconforming Product. Any such exchange of a Product shall be in accordance with HET's return materials authorization process.

	4.4
	Price. HET will sell Products to HS under the Agreement at the prices set forth in HET's price list in effect on the date of HET's
acceptance of HS's order. A copy of HET's price list 

4

 

in
effect on the Effective Date is attached as Exhibit D and such prices shall remain fixed throughout the Term so long as HS maintains
exclusivity pursuant to Sections 2.1 and 3.1. All prices are quoted in and payable in United States dollars, unless provided otherwise on the applicable invoice. 

	4.5
	Payment. HS will pay each of HET's invoices within thirty (30) days after receipt of the invoice. HET may at its discretion
refuse orders, require payment in full, ship C.O.D. or halt shipments in transit if any prior invoice is not paid in full or if HET deems such steps necessary to secure payment.

	4.6
	Taxes. The purchase prices and other amounts specified in this Agreement do not include sales, use or other applicable taxes, duties,
tariffs, or customs fees unless expressly stated to the contrary. HS will
pay all such taxes, duties, tariffs, deductions or withholdings (other than taxes based on HET's net income), imposed by any governmental authority (collectively,
"Taxes"), on any amounts payable to HET under this Agreement or from the licensing or providing to HS of Products. If HS is required to withhold any
Taxes from amounts due to HET under this Agreement, then HS agrees to increase the payment to HET so that, after payment of all Taxes, HS will have paid to HET the total amount due to HET as if no
Taxes were withheld. If a Tax may be avoided by providing a tax exemption certificate, then HS shall provide it to HET.

	4.7
	Interest. Any amount not paid when due will be subject to finance charges at the rate of one percent (1.0"%) per month or the maximum
rate permitted by applicable law, whichever is less, determined and compounded on a daily basis from the date due until the date paid. Payment of such finance charges will not excuse or cure HS's
breach or default for late payment. If HET retains a collection agency, attorney or other person or entity to collect overdue payments, all collection costs, including but not limited to reasonable
attorney's fees actually incurred, will be payable by HS.

	4.8
	Defective Product Returns. Authorization is required for all defective Product returns and a returned materials authorization
("RMA") number must be obtained prior to returning Product to HET.

	4.9
	Software Products. If HET indicates in this Agreement that HS will "purchase" or HET will "sell" (or similar words) Software Products,
then HET intends only that HS will receive a license to transfer such Software Product to its customers as provided in this Agreement. This Agreement does not grant HS any ownership rights in the
Software Products. HS agrees to not disassemble, decompile, reverse engineer, modify, or otherwise change any Software Product. HS understands that the Software Products are proprietary to HET or its
licensors and are subject to copyrights and trade secrets owned by HET or its licensors. HET represents and warrants that is owns (or has good and valid licenses with respect to) the Software Products
and that the Software Products do not (and when used, offered, sold or licensed pursuant to this Agreement, will not) infringe on any intellectual property rights of any third party. 

	5.
	SUPPORT.

	5.1
	By HS. Other than as set forth on Exhibit F, HS will be solely responsible for
performing, in a manner consistent with good industry practice, all installation, training and support of Products and other services requested or required by HS Affiliates, employees, agents and
customers or End Users who obtain Product from HS. HS shall not refer any HS Affiliate, employee, agent or customer or any End User to HET for such support. 

5

  

	5.2
	By HET. HET will provide to HS reasonable second-level maintenance and support services for the Products. Such maintenance and support
will be provided during HET's regular business hours (Monday through Friday, 8:30 a.m. to 5:00 p.m. MT, excluding holidays). Other than as set forth on  Exhibit F, HET has no
obligation under this Agreement to provide any services to, or respond to any requests from, HS's agents, customers or End
Users. However, HET reserves the right to establish and maintain contact with any HS agent, customer or End User in order to facilitate the second level support. 

	6.
	ADDITIONAL AGREEMENTS.

	6.1
	New Projects. HS and HET agree to use reasonable commercial efforts to work together to further define and, following such definition,
implement the following projects:

	(a)
	[*]

	(b)
	[*]

	6.2
	Insurance Reimbursement. HS agrees to use commercially reasonable efforts to (a) assist HET in identifying and qualifying
mutually beneficial opportunities to obtain medical insurance reimbursement for the use of the MedGem to measure metabolic rates, and (b) introduce third party insurance carriers to HET and
educate such insurers on the benefits of using the Products. There can be no assurance that such efforts to obtain insurance reimbursement and provide introductions to insurance carriers will be
successful. 

	7.
	PROPRIETARY RIGHTS.

	7.1
	Product Ownership. The Products and all worldwide Intellectual Property Rights therein are the exclusive property of HET and its
suppliers. All rights in and to the Products not expressly granted to HS in this Agreement are reserved by HET and its suppliers. Nothing in this Agreement will be deemed to grant, by implication,
estoppel, or otherwise, a license under any of HET's existing or future patents; HET agrees that it will not assert any of its rights under such patents against HS or its
Affiliates based upon the use, distribution, and sublicensing by HS or its Affiliates of the Products as permitted by this Agreement.

	7.2
	Trademark License. Subject to the terms and conditions of this Agreement, HET grants to HS for itself and its Affiliates a
non-exclusive, non-transferable (except as permitted under Section 12.2 (Assignment), revocable, royalty-free
license (without the right to grant sublicenses) to use and reproduce the HET Marks solely in connection with marketing the Products in the Markets. HS agrees to state in appropriate places on all
materials using the HET Marks that the HET Marks are trademarks of HET and to include the symbol TM or ® as appropriate. HET grants no rights in the HET Marks other than those
expressly granted in this Section 7.2. HS acknowledges HET's exclusive ownership of the HET Marks. HS agrees not to take any action inconsistent
with such ownership and to cooperate, at HET's request and expense, in any action (including the conduct of legal proceedings) which HET deems necessary or desirable to establish or preserve HET's
exclusive rights in and to the HET Marks. HS will not adopt, use, or attempt to register any trademarks or trade names that are confusingly similar to the HET Marks or in such a way as to create
combination marks with the HET Marks. HS will provide HET with samples of all products and materials that contain the HET Marks prior to their public use, distribution, or display for HET's quality
assurance purposes and will obtain HET's written approval before such use, distribution, or display which approval shall not be unreasonably withheld or delayed. At HET's request, HS will modify or
discontinue any use of the HET Marks if HET determines that such use does not comply with HET's then-current trademark usage policies and guidelines. 

6

 

	7.3
	Assignments. At the end of the Term, HS will assign to HET or such other person or entity as HET may designate all rights,
registrations, reservations, licenses, permits and similar items made or obtained by HS relating to the Products, the Trademarks, or any other proprietary rights of HET.

	7.4
	HS Intellectual Property Rights. Nothing in this Agreement shall give HET any license to or rights in any trademarks, service marks or
other intellectual property rights of HS, and HET shall not use any such intellectual property rights of HS with express prior written approval from HS. 

	8.
	WARRANTIES, REMEDIES AND DISCLAIMERS.

	8.1
	Hardware Product Warranty. HET warrants to and for the benefit of HS and its affiliates only that all Products (other than Software
Products), as delivered pursuant to Section 4.2 (Delivery), will be free from material defects in materials and workmanship in the course of
normal use in compliance with the instructions in the User Documentation. The period of the foregoing warranty (the "Hardware Warranty Period") shall be
(a) for MedGem devices used within HS facilities, twelve (12) months after delivery to HS, (b) for BodyGem device not used within HS facilities, fifteen (15) months after
delivery to HS or twelve (12) months after commercial sale to an End User, whichever is shorter; and (c) for Single Use Breathing Inserts, ninety (90) days after commercial sale
to an End User. If a returned
Product (other than Software Products) contains a material defect in materials or workmanship, then either (a) such defective Product will be repaired or replaced and returned to HS, freight
prepaid, or, at HET's election, (b) the amount paid by HS for such defective Product or media will be refunded to HS. HET shall have no responsibility or obligation with respect to any
deficiency resulting from accidents, misuse, or modifications of any Product.

	8.2
	Software Warranty. HET warrants to and for the benefit of HS and its affiliates only that, for a period of ninety (90) days
after commercial sale to an End User (the "Software Warranty Period"), the Software Products will operate substantially in accordance with the
specifications published by HET for such Software Product. If it is determined a Software Product does not operate substantially in accordance with the specifications published by HET for such
Software Product, then at HET's sole discretion, (a) such Software Product will be modified or replaced so that it does operate substantially in accordance with such specifications and returned
to HS, freight prepaid, or, at HET's election, (b) the amount paid by HS to HET for the Software Product which fails to so operate in accordance such specifications will be refunded to HS and
thereupon the license to use such Software Product shall terminate. HET shall have no warranty obligations whatsoever with respect to any Software Product which has been modified in any manner from
the form in which it was delivered by HET.

	8.3
	Warranties by Both Parties. Each party represents and warrants that it has full power and authority to enter into and perform this
Agreement, and the person signing this Agreement on such party's behalf has been duly authorized and empowered to enter into this Agreement. Each party represents and warrants it is free to enter into
and perform this Agreement without thereby being in breach of or default under the terms of any other contract, commitment or understanding.

	8.4
	Disclaimer. THE EXPRESS WARRANTIES IN SECTION 4.9 AND THIS SECTION 8 ARE IN LIEU OF,
AND HET DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, OR STATUTORY, REGARDING THE PRODUCTS, SERVICES, SOFTWARE OR THE USER DOCUMENTATION, INCLUDING ANY WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, TITLE, ACCURACY OF INFORMATION, NON-INFRINGEMENT OF THIRD-PARTY RIGHTS AND ARISING FROM THE COURSE OF DEALING 

7

 

BETWEEN
THE PARTIES OR USAGE OF TRADE. HS ACKNOWLEDGES THAT IT HAS RELIED ON NO WARRANTIES OTHER THAN THE EXPRESS WARRANTIES IN THIS AGREEMENT. HET WILL NOT, UNDER ANY CIRCUMSTANCE, BE LIABLE TO HS,
OR ANY END USER OR TRANSFEREE FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST PROFITS OR ANY OTHER SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES OF WHATEVER NATURE ARISING OUT OF THE
FOREGOING WARRANTY, THIS AGREEMENT OR RESULTING FROM THE DISTRIBUTION OF PRODUCTS BY HS OR THE USE BY ANY END USER OR ANY TRANSFEREE OF SUCH PRODUCTS, EVEN IF HET HAS BEEN NOTIFIED OF THE POSSIBILITY
OF SUCH DAMAGES. 

	9.
	OTHER OBLIGATIONS OF HS.

	9.1
	No Unauthorized Warranties. HS will not make or extend on behalf of HET any written or oral warranty in respect of any of the Products
except as may be contained in sales literature or brochures that are published or approved in writing by HET. HS will not advise, perform or demonstrate any use or application of any Product that is
not specifically approved in writing by HET. HS will not impair the sterility or integrity of the Products while they are in HS's custody.

	9.2
	Compliance With Laws. Both HET and HS represent and warrant that they thoroughly familiar with applicable laws, ordinances, regulations
other governmental requirements concerning the importation, handling, marketing, sale, demonstration, use and distribution of Products in the Markets. Both HET and HS will comply with all laws,
ordinances, regulations and other governmental requirements applicable to their businesses and to the importation, handling, marketing, sale, demonstration, use and distribution of Products pursuant
to this Agreement

	9.3
	U.S. Export Controls. Without limiting the generality of Section 9.2 (Compliance
With Laws), HS will not, directly or indirectly, export or re-export any Products, technical data associated with the Products, or the immediate Products (including, but not limited to,
processes, services, data and reports) derived from use of the Products from the Markets, without first obtaining the appropriate license from the United States Office of Export License from the
United States Office of Export Licensing or its successor.

	9.4
	Insurance. During the Term, HS will maintain liability insurance coverage issued by a responsible insurer satisfactory to HET as an
additional insured and afford HET not less than twenty (20) days advance notice of cancellation or material change in the policy. Upon HET's request, HS will provide a certificate of insurance
from the insurer certifying that coverage is in place. Also during the Term, HET will maintain liability insurance coverage issued by a responsible insurer satisfactory to HS as an additional insured
and afford HS not less than twenty (20) days advance notice of cancellation or material change in the policy. Upon HS's request, HET will provide a certificate of insurance from the insurer
certifying that coverage is in place.

	9.5
	Non-compete. HS warrants and agrees that it does not now and will not during the Term, without the prior written consent of
HET, directly or indirectly market, sell or promote any product in the Markets that measures resting metabolic rates or oxygen consumption, other than the Products. HS further warrants and agrees that
it will not manufacture or cause to have manufactured, nor purchase from a third party, any Single Use Breathing Inserts that are not approved in writing by HET. 

8

 

	10.
	TERM AND TERMINATION.

	10.1
	Term. Unless earlier terminated pursuant to this Section 10, the initial term
of this Agreement will begin on the Effective Date and expire on June 30, 2005 (the "Term"). The Term can be extended by mutual written agreement
by the parties.

	10.2
	Termination by HET. Upon the occurrence of any of the following, HET may terminate this Agreement by giving HS written notice of such
termination:

	(a)
	the
failure of HS to make any payment when due;

	(b)
	HS
directly or indirectly markets, sells or promotes any product in its areas of exclusivity that competes with any Product or has a significant financial interest in any company or
individual that is manufacturing, assembling, producing, marketing, selling or distributing any product that competes with any Product;

	(c)
	the
insolvency of HS, the filing of a petition in bankruptcy by or against HS, the appointment of a receiver for HS or its property, the execution of an assignment by HS of all or
substantially all of its assets for the benefit of its creditors, or the conviction of HS or any principal or manager of the HS for any crime tending to materially and adversely affect the ownership
or operation of its business; or

	(d)
	other
than as set forth in Section 10.2 (a) through (d), any failure by HS to perform any of its obligations under this
Agreement where such failure continues for thirty (30) days after written notice thereof by HET to HS. 

	10.3
	Termination by HS. Upon the occurrence of any of the following, HS may terminate this Agreement by giving HET written notice of such
termination:

	(a)
	the
insolvency of HET the filing of a petition in bankruptcy by or against HET, the appointment of a receiver for HET or its property, the execution of an assignment by HET of all or
substantially all of its assets for the benefit of its creditors, or the conviction of HET or any principal or manager of the HET for any crime tending to materially and adversely affect the ownership
or operation of its business;

	(b)
	any
failure by HET to perform any of its obligations under this Agreement where such failure continues for thirty (30) days after written notice thereof by HS to HET.

	(c)
	the
failure by HET to reasonably and timely provide Products in an amount and quality necessary to allow HS to meet its obligations hereunder; or

	(d)
	any
consistent or repeated failure of the Products to perform in accordance with their specifications or related documentation 

	10.4
	Effect of Termination.

	(a)
	Any
termination pursuant to Section 10.2 or 10.3 will be without prejudice to any other right or remedy afforded to either party
under this Agreement or any applicable law. In the event of termination, HS will:

	(i)
	not
have any further right to market, sell or distribute Products or perform Wellness Services in the Markets;

	(ii)
	furnish
HET with such information relating to the marketing, sale or distribution of Products and the provision of Wellness Services in the Markets as HET may reasonably request
(including information as to calls or the status of any negotiations for the sale of the Products); 

9

  

	(iii)
	return
to HET any Products, sales materials, manuals, price lists, and mailing lists provided by HET to HS for demonstration, promotional, or marketing purposes; and

	(iv)
	return
to HET any products that have not been committed for sale to a customer. HET will repurchase these Products for a price equal to the amounts paid to HET for such items. 

	10.5
	Standards of Performance. Each party acknowledges that the standards of performance imposed on it by this Agreement are reasonable and
that any failure of either party to comply fully with all of the terms and conditions set forth in this Agreement shall constitute a material breach and good cause for termination of this Agreement.

	10.6
	Acknowledgment. Any expiration or termination of the Term will be final and absolute. Each party waives any right, either express or
implied by applicable law or otherwise, to renewal of this Agreement or to any damages or compensation for any expiration or termination of the Term in accordance with this  Section 10. Each of the
parties has considered the possibility of such expiration or termination and the possibility of loss and damage resulting
therefrom in making expenditures pursuant to the performance of this Agreement. It is the express intent and agreement of the parties that neither will be liable to the other for damages or otherwise
by reason of the expiration or termination of the Term as provided for herein.

	10.7
	Survival. Section 1 (Definitions), Section 4.5 (Payment),  Section 4.6 (Taxes), Section 4.7 (Interest), Section 7.1
(Product Ownership), Section 7.3 (Assignments), Section 8
(Warranties, Remedies and Disclaimers), Section 10 (Termination), 11 (Limitation of Liability),
and Section 12 (Miscellaneous) will survive expiration or termination of this Agreement for any reason. In addition, with respect to a particular
product, the support obligations of both HET and HS set forth in Exhibit E and Exhibit F shall survive the termination of this Agreement for a period equal to the Hardware Warranty
Period or Software Warranty Period, as the case may be. 

	11.
	LIMITATION OF LIABILITY. HET'S LIABILITY (WHETHER IN TORT, CONTRACT OR OTHERWISE AND NOTWITHSTANDING ANY FAULT, NEGLIGENCE (WHETHER
ACTIVE, PASSIVE OR IMPUTED), PRODUCT LIABILITY, OR STRICT LIABILITY OF HET) UNDER THIS AGREEMENT OR WITH REGARD TO ANY PRODUCTS OR OTHER ITEMS FURNISHED UNDER THIS AGREEMENT WILL IN NO EVENT EXCEED
THE COMPENSATION PAID TO HET UNDER THIS AGREEMENT; PROVIDED, HOWEVER THAT
THE FOREGOING LIMITATION OF LIABILITY SHALL NOT APPLY TO ANY CLAIM BY ANY THIRD PARTY THAT THE PRODUCTS INFRINGE UPON THE VALID INTELLECTUAL PROPERTY RIGHTS OF SUCH THIRD PARTY, AS TO WHICH CLAIM HET
SHALL INDEMNIFY HS AND ITS AFFILIATES AND HOLD THEM HARMLESS FROM ANY COSTS, CHARGES, CLAIMS, DEMANDS OR LIABILITY WHATSOEVER. IN NO EVENT WILL HET BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR
CONSEQUENTIAL DAMAGES ARISING OUT OF ITS PERFORMANCE OR NONPERFORMANCE OF THIS AGREEMENT OR THE USE OF, INABILITY TO USE, OR RESULTS OF USE OF, ANY PRODUCT.

	12.
	MISCELLANEOUS.

	12.1
	Force Majeure. Neither party will be liable for, or be considered to be in breach of or default under this Agreement on
account of, any delay or failure to perform as required by this Agreement (other than for payments owed) as a result of any cause or condition beyond such party's reasonable control.

	12.2
	Assignment. Neither party may assign or transfer, by operation of law or otherwise, any of its rights under this
Agreement or delegate any of its duties under this Agreement to any 

10

 

third
party other than its Affiliates, without the other party's prior written consent. Such consent shall not be unreasonably withheld or delayed. Any attempted assignment or transfer in violation
of the foregoing will be void. 

	12.3
	Notice. Notices or consents under this Agreement will be in writing and delivered personally or, if mailed, will be sent
certified mail, return receipt requested, or by telex or facsimile or overnight express service, if addressed to the recipient's address set forth on the signature page of this Agreement, or in
either case to such other address as may be established by notice to the other party Notice will be effective only upon (and as of the date of) actual receipt.

	12.4
	Nonwaiver. The failure of either party to insist upon or enforce strict performance of any of the provisions of this
Agreement or to exercise any rights or remedies under This Agreement will not be construed as a waiver or relinquishment to any extent of such party' right to assert or rely upon any such provisions,
rights or remedies in that or any other instance; rather, the same will be and remain in full force and effect.

	12.5
	Interpretation. The headings of Sections of this Agreement are for convenience and are not to be used in
interpreting this Agreement. As used in this Agreement, the word "including" means "including but not limited to."

	12.6
	Severability. If any provision of this Agreement is unenforceable, such provision will be changed and interpreted to
accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions will continue in full force and effect. Without limiting the generality of
the foregoing, HS agrees that Section 11 (Limitation of Liability) will remain in effect notwithstanding the unenforceability of any provision in  Section 8 (Warranties, Remedies and Disclaimers).

	12.7
	Construction. This Agreement is the result of negotiations among, and has been reviewed by, HS and HET. Accordingly,
this Agreement shall be deemed to be the product of both parties hereto, and no ambiguity shall be construed in favor of, or against, HS or HET by reason of such party's role in drafting this
Agreement.

	12.8
	Counterparts. This Agreement may be executed in counterparts, each of which will be considered an original, but all of
which together will constitute the same instrument.

	12.9
	Governing Law; Venue. The rights and obligations of the parties under this Agreement shall be governed in all respects
by the laws of the State of Colorado exclusively, as such laws apply to contracts between Colorado residents performed entirely within Colorado.

	12.10
	Arbitration. The parties agree to make every reasonable effort to amicably settle any controversy between them relating
to the terms and conditions and subject matter of this Agreement. In the event that the parties are unable to reach an amicable settlement regarding any controversy relating to the terms, conditions
or subject matter of this Agreement, the parties agree that, within 30 days following written notice of a request for arbitration served by one of the parties upon the other, they shall submit
such controversy to a single, independent, unbiased arbitrator. The arbitration will be carried out in accord with the rules of the American Arbitration Association at a mutually agreeable location.
Discovery will be carried out in accord with the Federal Rules of Civil Procedure and, should said rules be in conflict with any of the rules of the American Arbitration Association, the
Federal Rules shall prevail. In the event the parties cannot agree upon a single arbitrator within 20 days following a written request for arbitration, the arbitrator will be selected by
the American Arbitration Association. The decision of the arbitrator will be final and binding upon both parties. Upon application by either party, the decision of the arbitrator may be entered as a
final award or judgment by any court of competent jurisdiction in the United States of America. 

11

 

	12.11
	Confidentiality of Agreement. Neither party will disclose the terms of this Agreement to anyone other than its
Affiliates, attorneys, accountants, and other professional advisors under a duty of confidentiality except (a) as required by law; or (b) pursuant to a mutually acceptable press release;
or (c) in connection with a proposed merger, financing, or sale of such party's business (provided that any
third party to whom the terms of this Agreement are to be disclosed signs a confidentiality agreement reasonably satisfactory to the other party of this Agreement).

	12.12
	Entire Agreement; Amendments. This Agreement contains the entire agreement, and supersedes any and all prior
agreements, between the parties with regard to the subject matter hereof. HET will not be bound, and specifically objects to, any terms, conditions, or other provisions that are different from or in
addition to the provisions of this Agreement (whether or not it would materially alter this correspondence, or otherwise). Without limiting the generality of the foregoing, any printed terms,
conditions of other provisions that are included in or accompany any of HS's orders for Products under this Agreement will not apply or be binding on HET. This Agreement may not be waived, amended or
rescinded except by a writing signed by the party to be charged thereby. 

        In Witness Whereof, the parties have executed this Agreement as of the Effective Date. 

	
HealtheTech, Inc.	
 	

HEALTHSOUTH CORPORATION
	
By:	
 	

/s/  JAMES R. MAULT      
 James R. Mault, MD

Chairman and CEO	
 	

By:	
 	

/s/  WILLIAM T. OWENS      
 William T. Owens

President and COO

12

 

*    Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

Schedule I

Excluded Accounts  

[*] 

13

   Exhibit A

PRODUCT LIST  

	1.
	Products.

	(a)
	The
HET BodyGemTM Metabolic Measurement Device and its associated disposable Single-Use Breathing Inserts (disposable mouthpieces or facemasks).

	(b)
	The
HET MedGemTM Metabolic Measurement Device and its associated disposable Single-Use Breathing Inserts (disposable mouthpieces or facemasks).

	(c)
	HET's
BalanceLogTM Software.

	(d)
	MedGem
and BodyGem Analyzer SoftwareTM.

	(e)
	GlucoPilotTM 

The
parties can add products by mutual written agreement. 

14

   
*    Portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

Exhibit B

PURCHASE Commitments  

        HS's Purchase Commitments are defined below, by periods (each a "Period") for calendar years 2002, 2003 and 2004
and the first half of 2005. (For subsequent calendar years during the Term, the parties agree to use best efforts to negotiate and mutually agree upon new Purchase Commitments for the coming calendar
year by the November 30 preceding the start of such year.) 

	1.
	Purchase Commitment. The Purchase Commitments are as follows: 

	Purchase Commitment

	Period
 
	 	Amount

	Effective Date through 12/31/02	 	$	[*]
	1/1/03 through 6/30/03	 	$	[*]
	1/1/03 through 12/31/03	 	$	[*]
	1/1/04 through 12/31/04	 	$	[*]
	1/1/05 through 6/30/05	 	$	[*]

15

 
Exhibit C

TRADEMARKS  

Trademarks
and trade names of HET: 

HET
(name and stylized mark)

BodyGem

Your Body Is Talking. Listen.

BalanceLog

Calorie Checkbook

Listen To Your Body

MedGem

Glucopilot 

16

 

*    Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

Exhibit D

PRICE LIST  

	1.
	BodyGemTM
Metabolic Measurement Device: $[*] per unit 
	2.
	MedGemTM
Metabolic Measurement Device: $[*] per unit 
	3.
	BalanceLogTM
Software. 
	a.
	BalanceLog
for Windows: $[*]/each (packaged on CD) 
	b.
	BalanceLog
for Windows and Palm OS: $[*]/each (packaged on CD) 
	c.
	BalanceLog
for Windows—downloaded from HET website: $[*] each 
	d.
	BalanceLog
for Windows and Palm OS—downloaded from HET website: $[*] each 

	4.
	MedGem
Analyzer Software: $[*] 
	5.
	BodyGem
Analyzer Software: $[*] 
	6.
	Disposables
for MedGem and BodyGem: $[*] per disposable (packaged in boxes of 20). 
	7.
	Flow
tubes (packaged in boxes of 20): $[*] 
	8.
	Nose
Clips, molded plastic (set of 20): $[*] 
	9.
	Nose
Clips, foam padded (set of 20): $[*] 
	10.
	Battery
Pack: $[*] 
	11.
	GlucoPilot
software: $[*] 

Payment
for the full ordered quantity on the purchase order will be invoiced at one time and full payment for the entire quantity must be made net thirty (30) days from the date of invoice per  Section 4.5 (Payment). 

17

   EXHIBIT E

HS OBLIGATIONS  

        HS shall, during the Term, perform the following obligations and shall cause each Affiliate of HS to perform the following obligations: 

	(i)
	For
sales made by HS pursuant to section 2.1 (b), HS will provide to initial training to applicable Affiliates, employees and agents, Affiliate employees and agents and
customers and End Users. Such initial training shall include education on metabolism, resting metabolic rate, energy balance equations, operation of the MedGem device, and information on BalanceLog
software features and functionality.

	(ii)
	Provide
Customer Support (as defined below) to all HS Affiliates, employees, agents, customers, End Users and Affiliate employees and Agents during regular HS customer
support hours throughout the Hardware Warranty Period or software Warranty Period, as the case may be. After the initial Hardware Warranty Period or software Warranty Period expires, HS may
offer extended warranties or additional customer service to its Affiliates, agents and End Users at HS standard rates. The products supported by HS Customer Support obligations under this Agreement
include the MedGem and BodyGem metabolic measurement devices and the HET BalanceLogTM software. 

For
purposes of this Exhibit E, "Customer Support" shall mean technical phone support, email support, and customer phone service. Technical phone support is the delivery of technical assistance
to HEALTHSOUTH Affiliates, employees and Agents and Affiliate employees and agents and End Users, including technical assistance, troubleshooting and authorization of product repair for warranty
service. Customer Service Support provides answers to frequently asked questions, resolves shipping problems, processes re-orders for Customer products, logs customer comments and
complaints. 

	(iii)
	Use
its best efforts to market and provide Wellness Services to customers within its areas of exclusivity.

	(iv)
	Acknowledge
that the BodyGem device being supplied to HS by HET is not a medical device, is not approved or cleared by the U.S. Food and Drug Administration (FDA) as a medical
device, and is not
being offered by HET as a medical device. HS agrees not to make any medical claims about the BodyGem or BalanceLog. The terms in this clause do not apply to the MedGem devices.

	(v)
	Order
from HET HS's full requirements of supply for the BodyGem, MedGem and/or components thereof, and not use any non-HET approved Disposable components with the BodyGem
or MedGem metabolic measurement device. HS acknowledges that use of any non-HET approved breathing insert (mouthpiece or facemask) with the BodyGem or MedGem device voids the warranty for
such device and may cause the device to operate inaccurately.

	(vi)
	Acknowledge
that the Single Use Breathing Inserts are disposable components and are not intended for re-use and that any re-use may present a risk of
transmission of infectious or communicable diseases. HS agrees that it and its Affiliates will discard the Single Use Breathing Inserts at the end of a successful measurement. HS agrees it shall
instruct and cause all of its Affiliates not to re-use the Single Use Breathing Inserts, or otherwise misuse the BodyGem or MedGem devices in a way that is not consistent with HET provided
instructions for use located in the BodyGem or MedGem User Documentation. 

18

 

	(vii)
	Provide
appropriate and professional application advice and counseling for each Product sold by HS, and provide prompt follow-up service and advice to purchasers of
Products when so requested by the purchaser.

	(viii)
	Maintain
and furnish periodically, as reasonably requested by HET, complete and accurate records of sale of each Product sold under this Agreement (e.g., showing the date of sale,
name and address of the purchaser and the Product serial number or lot number). For units used internally report the number of units actively in use and the approximate number of measurements per day
per units.

	(ix)
	Allow
HET, with prior approval from HS, which approval shall not be unreasonably withheld, access to visit any HS or Affiliate location during normal business hours or
accompany any HS employee detailing, selling or explaining MedGem to any end user and at HET's sole expense to conduct a review of the HS or Affiliate facilities and their Products' capabilities and
if applicable, make suggestions for improvement based upon HET's experience with the Products. HS agrees to consider such suggestions and make changes it believes, in HS's sole discretion, are
reasonable.

	(x)
	Allow
HET access to visit any HS or Affiliate, customer or end user location during normal business hours at HET's sole expense, to upgrade or exchange out (with upgraded
units) HS's Affiliate's, customer's or End User's MedGem or BodyGem devices when and if HET deems appropriate. 

19

   
*    Portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

EXHIBIT F

TRAINING AND SUPPORT OBLIGATIONS  

        HET shall, during the Term, perform the following training and support obligations: 

	(i)
	HET
will provide to designated HS personnel, at HS facilities, initial training. Such initial training shall include education on metabolism, resting metabolic rate, energy balance
equations, operation of the BodyGem and MedGem devices, and information on BalanceLog software features and functionality. All training shall be scheduled by mutual agreement by the parties and shall
be provided in 3-hour training session blocks. Each "training session" is scheduled as 3 consecutive hours during normal business hours M-F, but may take less
than 3 hours to conduct depending upon the composition of the group being trained. HS shall be responsible for providing all training facilities and notifying and scheduling the training
audience. All training must be scheduled by HS with HET one month in advance and must be scheduled in full-day (two 3 hour sessions) increments whenever possible. For training
purposes, [*] with the initial order to each such location. The initial training shall be provided by HET in two categories: No-Charge Training and
For-Fee Training as specified below.

	(a)
	No-Charge Training—HET shall provide at no charge a total of [*] to HS, with the
training sessions performed in mutually agreed upon locations.

	(b)
	For-Fee Training—HET shall provide additional on-site training sessions for a fee of
$[*] per hour, per HET trainer and shall be charged in [*] increments plus all HET travel expenses associated with the delivery of such training. 

	(ii)
	If
requested by HS, HET will provide on-going MedGem, BodyGem and BalanceLog training beyond the initial training specified above to HS operated facilities personnel on
the following basis:

	(a)
	All
on-going training shall be charged at a rate of [*] per hour, per HET trainer, and shall be charged in [*] increments.
HS must provide its own MedGem metabolic measurement device and Single Use Breathing Inserts for use in the training sessions.

	(b)
	All
fees and expenses shall be invoiced by HET and reimbursed by HS within 30 days of date of invoice.

	(c)
	HET
shall use all reasonable efforts to accommodate the time and place for HS requested on-going training, but any on-going training shall be scheduled by
mutual agreement of the parties.

	(d)
	In
order to provide reasonable notice to HET of known or anticipated HS training requirements, HS agrees to give non-binding good faith training demand forecasts at the
beginning of each month for the following 60 day period during the Term of this Agreement. All forecasts shall be in writing and shall specify the number of attendees and the desired location
and duration. 

	(iii)
	Customer Support. HET shall provide Customer Support (as defined below) to HS employees during regular HET customer
support hours (currently 8:30am to 5:00pm MST, Monday—Friday, excluding major holidays) throughout the Hardware Warranty Period or Software Warranty Period, as the case may be.
After the initial warranty period expires, extended warranties or additional customer service can be purchased at HET standard rates. The products supported by HET Customer Support obligations under
this Agreement include the MedGem metabolic measurement device and the HET BalanceLogTM software. HET does not 

20

 

support
or troubleshoot any other HS specific hardware or software, nor any other third party software or hardware, unless specifically agreed to and priced by mutual written agreement of the
parties. 

        For
purposes of this Exhibit F, "Customer Support" shall mean technical phone support, email support, and customer phone service. Technical phone support is the delivery of
technical assistance to HEALTHSOUTH Affiliates and employees including technical assistance, troubleshooting and authorization of product repair for warranty service. Customer Service Support provides
answers to frequently asked questions, resolves shipping problems, processes re-orders for Customer products, logs customer comments and complaints. 

21

QuickLinks

EXHIBIT 10.37

HS-HET STRATEGIC AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document
  

CONFIDENTIAL TREATMENT REQUEST  

  
 

    EXHIBIT 10.38    
  

*    Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

PROMOTION AGREEMENT  

        This Promotion Agreement ("Agreement") is made and entered into as of this 23rd day of May, 2002
("Effective Date"), by and between HealtheTech, Inc., a Delaware corporation having its principal
place of business at 523 Park Point Drive, Third Floor, Golden, Colorado 80401 USA ("HET"), and HEALTHSOUTH
Corporation, located at One Healthsouth Parkway, Birmingham, Alabama 35243 ("HS"). 

Recitals

        A.    HS
is the owner or licensee of certain media properties referred to as HS Properties (as further defined below). 

        B.    HET
is a personal health monitoring company that develops, manufactures, and markets various devices, software, and services for consumer health, fitness, and nutrition
("HET Business"). 

        C.    HS
and HET wish to establish a relationship through which HS will promote the HET Business through the HS Properties. 

        NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, HS and HET hereby agree as follows: 

Agreement

	1.
	Definitions.

        1.1  "Advertising Content" means the HET Content and HS Content. 

        1.2  "Affiliate" means, with respect to a party, any person or entity that controls, is controlled by, or is under common
control with such party, where "control" means ownership of fifty percent (50%) or more of the outstanding voting securities (but only as long as such person or entity meets these requirements). 

        1.3  "HET Marks" means the trademarks, service marks and trade names of HET listed in Attachment
C (as such list may be updated from time to time by HET upon notice to HS). 

        1.4  "HS Properties" means those publications listed in Attachment A. 

        1.5  "HS Content" are those advertising content and materials relating to the HET Business which is created in whole or part
by or for HS pursuant to this Agreement or which were pre-existing prior to the Effective Date of this Agreement, but which HS proposes to use to promote the HET Business pursuant to the
terms of this Agreement, and as further described in Attachment A-1. 

        1.6  "HET Content" means those advertising content and materials relating to the HET Business that are created solely by HET,
or for HET (excluding all HS Content) and as further described in Attachment A-1. 

        1.7  "Third Party Content" means that HS Content as to which HS does not have the legal right to transfer ownership to HET
pursuant to the terms of this Agreement. 

1

 

	2.
	HS Obligations.

        2.1  Advertisements. HS agrees to create, at its expense, and with HET's cooperation and under its
creative supervision and direction, advertising materials as further described in Attachment A-1. All Advertising Content shall be subject
to the prior written approval of HET prior to any distribution or display to third parties. 

        2.1.1    Ownership of HET Advertising Content. Unless otherwise agreed in writing by HET,
all HET Content shall be the property of HET. As such, all intellectual property rights in such materials belong to HET. HS hereby irrevocably transfers, conveys and assigns to HET in perpetuity all
right, title, and interest in such HET Content, including without limitation all copyrights, including the right to make derivative works and collective works with respect thereto, it being
understood, however, that HS has, and transfers, no rights with respect to any underlying HET Content. HET will have the exclusive right to apply for or register copyrights and such other proprietary
protections as it wishes. HS agrees to execute such documents, render such assistance, and take such other action as HET may reasonably request at HET's expense, to apply for, register, perfect,
confirm, and protect HET's rights in the HET Content including (without limitation) an assignment of copyright. Without limiting the foregoing, HET will have the exclusive right to commercialize,
prepare and sell products based upon, sublicense, prepare derivative works from, or otherwise use or exploit the HET Content. HS hereby waives any and all moral rights, including any right to
identification of authorship or limitation on subsequent modification that HS (or its employees, agents or consultants) has or may have in any HET Content. HET shall have sole discretion to deal with
and to modify the HET Content and to decide whether, to what extent, with what credits and in what final form to use the materials in any country and in any media without additional payment by HET. 

        2.1.2    Third Party Content. To the extent HS is unable to obtain ownership of
Advertising Content provided by third party, (1) HS shall provide written notice to HET identifying such Third Party Content, and (2) HS shall use its commercially reasonable efforts to
obtain all necessary permissions and releases from third parties whose images or properties are used in the Advertising Content. Accordingly, if, and to the extent (and only to the extent) that HS
obtains such permissions and releases HS hereby grants (on behalf of itself and its licensors) a worldwide, non-exclusive, fully paid up irrevocable and perpetual right and license to HET
and its Affiliates to use, reproduce, display, transmit, sublicense and create derivative works of such Third Party Content in connection with the promotion of the HET Business (including without
limitation the right to make adaptations, translations and revisions and in any form or type of media existing now or in the future, but only to the extent permissible under the applicable permissions
and releases). Such licenses, permissions and releases are to be in a form reasonably acceptable to HET. Unless otherwise agreed by HET, such use license shall be exclusive for the intended market,
with no requirement for payment of any additional
or residual creative rights fees for any later or subsidiary uses including merchandising and dealer support and detailing programs that HET may implement. 

        2.2  Promotion. HS agrees to promote the HET Business on the HS Properties in accordance with the  Attachment A attached
hereto. HS guarantees that during the Term, HS shall provide HET with the number of placements and delivered impressions outlined
in Attachment A. The value of such placements and delivered impressions shall be equal to at least $[*] as indicated by the
document provided by HS to HET on April 23, 2002, which is attached as Attachment A-2. 

        2.3  Reports. HS will provide HET with a monthly report summarizing the previous month's promotions
and the location of such promotions within five (5) business days following the end of such month. 

2

 

        2.4  Make Good. In the event that any report required by  Section 2.3 indicates that HS has not made any placement or
impression required in Attachment A
on a timely basis, upon written approval by HET, HS shall make a comparable substitute placement or impression within ninety (90) days of such notice and report the same to HET. The remedies
provided to HET under this Section 2.4 are not exclusive, but are in addition to any other remedies that HET may have under law. 

        2.5  Conflicts. HS certifies that HS has no outstanding agreement or obligation that is in conflict
with any of the provisions of this Agreement, or that would preclude HS from complying with the provisions hereof, and further agrees that HS will not enter into any such conflicting Agreement during
the term of this Agreement. 

        2.6  Printing Services. Upon the request of HET, HS agrees to enter into a separate mutually
acceptable agreement with HET under which HS will provide printing services for HET marketing materials, stationery and the like at HS's Cost plus twenty percent (20%). As volume increases, the
parties may negotiate lower prices. 

        2.7  No Disparagement. HS shall not use the HET name or marks in a manner that disparages or causes
damage to the HET Business. HS shall not make any representations, warranties, guarantees, or other written or oral statements made by or on behalf of HS relating to the HET Business other than as
authorized by HET in writing. 

	3.
	HET Obligations.

        3.1  Assistance. HET shall provide its reasonable assistance to HS in connection with HS's obligations
under Section 2 above and Attachment A, including providing creative direction and feedback to HS regarding Advertising Content. In addition, in accordance with Attachment A-1, HET
shall provide the HET Content. 

        3.2  Conflicts. HET certifies that HET has no outstanding agreement or obligation that is in conflict
with any of the provisions of this Agreement, or that would preclude HET from complying with the provisions hereof, and further agrees that HET will not enter into any such conflicting Agreement
during the term of this Agreement. 

        3.3  No Disparagement. HET shall not use the HS name or marks in a manner that disparages or causes
damage to the HS Business. HET shall not make any representations, warranties, guarantees, or other written or oral statements made by or on behalf of HET relating to the HS Business other than as
authorized by HS in writing. 

	4.
	Consideration.

        4.1  Promotion. In consideration for the promotion services provided herein, HET agrees to issue to
HS, upon the closing of the initial public offering by HET of its Common Stock, par value $0.001 per share (the "Common Stock"), a warrant,
substantially in the form attached as Attachment B, to purchase an aggregate number of Common Stock equal to 10% of the total number of shares of Common
Stock outstanding immediately prior to the closing of the initial public offering, at an exercise price per share equal to the per share price to the public (without regard to any underwriting
discounts or commissions) of the Common Stock sold in the initial public offering. For purposes of this Section 4.1, all shares of Common Stock
issuable upon the exercise of stock options or warrants or the conversion of preferred stock of the Company, in each case outstanding immediately prior to the closing of the initial public offering,
shall be deemed to be outstanding. 

        4.2  HS Content. There shall be no additional charge to HET for the provision of the HS Content. 

        4.3  Costs. Except as expressly provided for under this Agreement, each party shall bear its own costs
in connection with its performance of this Agreement. 

3

 

        5.    Licenses.

        5.1  Advertising Content. Subject to the terms and conditions of this Agreement, HET grants to HS and
its Affiliates a non-exclusive, non-transferable (except as permitted under Section 12.2 (Assignment), revocable,
royalty-free license (without the right to grant sublicenses) to use and reproduce the Advertising Content solely in connection with HET-approved promotion of the HET Business
pursuant to this Agreement. As between HS and HET, HET shall own all right, title and interest in the Advertising Content excluding the Stories. Stories or story shall mean editorial or creative
content other than advertising. HS shall not modify or translate any Advertising Content or make any representations, guarantees or promises on behalf of HET without the prior written permission of
HET. HET reserves all rights in the Advertising Content, except for the limited license expressly set forth herein. 

        5.2  Trademark License. Subject to the terms and conditions of this Agreement, HET grants to HS and
its Affiliates a non-exclusive, non-transferable (except as permitted under Section 12.2 (Assignment), revocable,
royalty-free license (without the rights to grant sublicenses) to use and reproduce the HET Marks solely in connection with HET-approved promotion of the HET Business pursuant
to this Agreement and in accordance with the HET guidelines for such HET Marks. HS agrees to state in appropriate places on all materials using the HET Marks that the HET Marks are trademarks of HET
and to include the symbol TM or ® as appropriate. HET grants no rights in the HET Marks other than those expressly granted in this  Section 5.2. 

        5.2.1    HS acknowledges HET's exclusive ownership of the HET Marks. HS agrees not to take
any action inconsistent with such ownership and to cooperate, at HET's request and expense, in any action (including the conduct of legal proceedings) that HET deems necessary or desirable to
establish or preserve HET's exclusive rights in and to the HET Marks. HS will not adopt, use, or attempt to register any trademarks or trade names that are confusingly similar to the HET Marks or in
such a way as to create combination marks with the HET Marks. HS will provide HET with samples of all products and materials that contain the HET Marks prior to their public use, distribution, or
display for HET's quality assurance purposes and will obtain HET's written approval, which shall not be unreasonably withheld or delayed, before such use, distribution, or
display.

        5.2.2    At HET's request, HS will modify or discontinue any use of the HET Marks if HET
determines that such use does not comply with HET's then-current trademark usage policies and guidelines. HS shall not use the HET Marks in a manner that disparages or causes damage to the
HET Business.

        5.2.3    HS will assign to HET or such other person or entity as HET may designate all
rights, made or obtained by HS relating to the HET Marks.

	6.
	Representations and Warranties. The representations and warranties and covenants in this  Section 6 are
continuous in nature and shall be deemed to have been given by the applicable parties at execution of this Agreement and at each
stage of performance hereunder. 

        6.1  Corporate Power. Each party hereby represents and warrants that such party is duly organized and
validly existing under the laws of the state of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 

        6.2  Due Authorization. Each party hereby represents and warrants that such party is duly authorized
to execute and deliver this Agreement and to perform its obligations hereunder and that this Agreement is a legal and valid obligation binding upon it and enforceable with its terms. Each party hereby
further represents and warrants that the execution, delivery and performance of this Agreement by such party does not conflict with any agreement, instrument or understanding, oral or written, to
which it is a party or by which it may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

4

 

        6.3  Intellectual Property Rights.

        6.3.1    HS represents that it is the owner or is licensed to use the HS Content and Third Party Content provided
to HET pursuant to the terms of this Agreement, including, without limitation, (a) the names and/or pictures of persons; (b) any copyrighted material, trademarks, service marks, logos,
and/or depictions of trademarked or service marked goods or services; and (c) any testimonials or endorsements contained in any advertisement submitted to HET. HS has the full and exclusive
right to grant, and provide the promotion services described herein, with respect to the HS Properties. 

        6.3.2    HET represents that it is the owner or is licensed to use the HET Content provided to HS pursuant to the
terms of this Agreement, including, without limitation, (a) the names and/or pictures of persons; (b) any copyrighted material, trademarks, service marks, logos, and/or depictions of
trademarked or service marked goods or services; and (c) any testimonials or endorsements contained in any advertisement submitted to HS. 

        6.4  EXCEPT AS EXPRESSLY WARRANTED IN SECTION 6 ABOVE, BOTH PARTIES EXPRESSLY
DISCLAIMS ANY FURTHER WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND
NON-INFRINGEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY MAKES NO EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE CONTENT PROVIDED BY SUCH PARTY,
THE PARTY'S RESPECTIVE BUSINESS OR ANY PRODUCTS OR SERVICES OFFERED OR SOLD THROUGH SUCH PARTY (INCLUDING, WITHOUT LIMITATION, WARRANTIES OF FITNESS, MERCHANTABILITY, NON-INFRINGEMENT OR
ANY IMPLIED WARRANTIES ARISING OUT OF A COURSE OF PERFORMANCE, DEALING OR TRADE USAGE). HET SHALL
HAVE NO LIABILITY TO HS TO THE EXTENT THAT HS CONTINUES TO USE, TRANSMIT OR DISPLAY ANY HET CONTENT AFTER HET'S WRITTEN REQUEST TO HS TO CEASE SUCH ACTIVITY. 

	7.
	Term. Unless earlier terminated pursuant to this  Section 7, the initial term of this Agreement will begin on
the Effective Date and expire on June 30, 2005 (the
"Term"). The Term can be extended by mutual written agreement by the parties. 

        7.1  Termination by HET. Upon the occurrence of any of the following, HET may terminate this Agreement
by giving HS written notice of such termination: 

        (a)  HS
disparages the HET Business or promotes products and services that compete with the products and services offered by HET as part of the HET Business; 

        (b)  the
insolvency of HS, the filing of a petition in bankruptcy by or against HS, the appointment of a receiver for HS or its property, the execution of an assignment by HS
of all or substantially all of its assets for the benefit of its creditors, or the conviction of HS or any principal or manager of the HS for any crime tending to adversely affect the ownership or
operation of its business; or 

        (c)  any
failure by HS to perform any of its obligations under this Agreement where such failure continues for thirty (30) days after written notice thereof by HET to
HS. 

        7.2  Termination by HS. Upon the occurrence of any of the following, HS may terminate this Agreement
by giving HET written notice of such termination: 

        (a)  the insolvency of HET, the filing of a petition in bankruptcy by or against HET the appointment of a receiver for HET or
its property, the execution of an assignment by HET of all or substantially all of its assets for the benefit of its creditors, or the conviction of HET or any 

5

 

principal or manager of the HET for any crime tending to adversely affect the ownership or operation of its business; or 

        (b)  HET disparages the HS Business or promotes products and services that compete with the products and services offered by
HS as part of the HS Business; 

        (c)  any failure by HET to perform any of its obligations under this Agreement where such failure continues for thirty
(30) days after written notice thereof by HS to HET. 

        7.3  Effect of Termination. Any termination pursuant to Section 7.1 or
7.2 will be without prejudice to any other right or remedy afforded to either party under this Agreement or any applicable law. In the event of termination or expiration, HS
shall return all Advertising Content (excluding the Stories) to HET. 

        7.4  Survival. Section 1
(Definitions), Section 2.1.1and 2.1.2 (Ownership), Sections 5.2.1,
5.2.2, 5.2.3 (Trademark Restrictions), Section 6.4 (Warranty Disclaimer),  Section 7 (Termination), Section 8(Confidentiality),  Section 9 (Limitation of Liability), Section 11 (Audit Rights) and
Section 12 (Miscellaneous) will survive expiration or termination of this Agreement for any reason. 

	8.
	Confidentiality.

        8.1  Confidentiality of Agreement. Neither party will disclose any terms of this Agreement to anyone
other than its Affiliates, attorneys, accountants, and other professional advisors under a duty of confidentiality except (a) as required by law; or (b) pursuant to a mutually agreeable
press release; or (c) in connection with a proposed merger, financing, or sale of such party's business (provided that any third party to whom the terms of this Agreement are to be disclosed
signs a confidentiality agreement reasonably satisfactory to the other party to this Agreement). ). Notwithstanding the foregoing, HET may disclose, and HS hereby consents to the disclosure of, the
relationship of HET with HS, including (i) the use of HS's name as a customer, distributor and/or strategic partner, (ii) the use of HS's logo and (iii) the use of statements
regarding (a) HS and its business, (b) the relationship between HS and HET and/or (c) the products, licenses and/or services received from, or furnished to, HET and/or HS, in the
proposed registration statement on Form S-1 to be filed in connection with HET's initial public offering. Furthermore, HET may file, and HS consents to the filing of, the
agreement(s) between HS and HET as an exhibit to the Registration Statement. 

	9.
	Relationship of Parties. HS is an independent contractor and not an agent, employee, franchise or partner of
HET, and is acting in the ordinary course of business. HS does not have any authority to, and will not create or assume any obligation, express or implied, on behalf of HET. HS shall be responsible
for all taxes and payments concerning HS, its employees and its sales representatives. This Agreement does not create or evidence any joint venture or partnership of the parties.

	10.
	Audit RIGHTS. HS will maintain complete, clear and accurate records of all promotions performed for HET under
this Agreement. HS shall make such records available to HET within 30 days of notice from HET. HS shall "make good" (provide the promotions pursuant to Section 2 above) any deficiency
discovered through a review of the records within thirty (30) days after the receipt of notice thereof.

	11.
	MISCELLANEOUS.

        11.1 Force Majeure. Neither party will be liable for, or be considered to be in breach of or default
under this Agreement on account of, any delay or failure to perform as required by this Agreement (other than for payments owed) as a result of any cause or condition beyond such party's reasonable
control. 

        11.2 Assignment. Neither party may assign or transfer, by operation of law or otherwise, any of its
rights under this Agreement or delegate any of its duties under this Agreement to any third party other 

6

 

than its Affiliates, without the other parties prior written consent. Any attempted assignment or transfer in violation of the foregoing will be void. 

        11.3 Notice. Notices or consents under this Agreement will be in writing and delivered personally or,
if mailed, will be sent certified mail, return receipt requested, or by telex or facsimile or overnight express service, if addressed to the recipient's address set forth on the signature
page of this Agreement, or in either case to such other address as may be established by notice to the other party Notice will be effective only upon and as of the date of actual receipt. 

        11.4 Nonwaiver. The failure of either party to insist upon or enforce strict performance of any of
the provisions of this Agreement or to exercise any rights or remedies under this Agreement will not be construed as a waiver or relinquishment to any extent of such party' right to assert or rely
upon any such provisions, rights or remedies in that or any other instance; rather, the same will be and remain in full force and effect. 

        11.5 Interpretation. The headings of Sections of this Agreement are for convenience and are
not to be used in interpreting this Agreement. As used in this Agreement, the word "including" means, "including but not limited to." 

        11.6 Severability. If any provision of this Agreement is unenforceable, such provision will be
changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions will continue in full force and effect. 

        11.7 Construction. This Agreement is the result of negotiations among, and has been reviewed by, HS
and HET. Accordingly, this Agreement shall be deemed to be the product of both parties hereto, and no ambiguity shall be construed in favor of, or against, HS or HET. 

        11.8 Counterparts. This Agreement may be executed in counterparts, each of which will be considered
an original, but all of which together will constitute the same instrument. 

        11.9 Governing Law; Venue. The rights and obligations of the parties under this Agreement shall be
governed in all respects by the laws of the State of Colorado exclusively, as such laws apply to contracts between Colorado residents performed entirely within Colorado. 

        11.10    Arbitration. The parties agree to make every reasonable effort to amicably settle
any controversy between them relating to the terms and conditions and subject matter of this Agreement. In the event that the parties are unable to reach an amicable settlement regarding any
controversy relating to the terms, conditions or subject matter of this Agreement, the parties agree that, within 30 days following written notice of a request for arbitration served by one of
the parties upon the other, they shall submit such controversy to a single, independent, unbiased arbitrator. The arbitration will be carried out in accord with the rules of the American Arbitration
Association at a mutually acceptable location. Discovery will be carried out in accord with the Federal Rules of Civil Procedure and, should said rules be in conflict with any of the rules of
the American Arbitration Association, the Federal Rules shall prevail. In the event the parties cannot agree upon a single arbitrator within 20 days following a written request for
arbitration. The arbitrator will be selected by the American Arbitration Association. The decision of the arbitrator will be final and binding upon both parties. Upon application by either party, the
decision of the arbitrator may be entered as a final award or judgment by any court of competent jurisdiction in the United States of America. 

        11.11    Entire Agreement; Amendments. This Agreement contains the entire agreement, and
supersedes any and all prior agreements, between the parties with regard to the subject matter hereof. HET will not be bound be, and specifically objects to, any terms, conditions, or other provisions
that are different from or in addition to the provisions of this Agreement (whether or not it would materially alter this correspondence, or otherwise).    This Agreement may not be
waived, amended or rescinded except by a writing signed by the party to be charged thereby. 

7

 

        In Witness Whereof, the parties have executed this Agreement as of the Effective Date. 

	
HEALTHETECH, INC.	
 	

HEALTHSOUTH CORPORATION
	

By:	
 	

/s/  JAMES R. MAULT      
 James R. Mault, MD

Chairman and CEO	
 	

By:	
 	

/s/  WILLIAM T. OWENS      
 William T. Owens

President and COO
	

Date:	
 	

 	
 	

Date:	
 	

 
	 	 	
	 	 	 	

8

   
*    Portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

ATTACHMENT A

Promotion

	1.
	Promotion of HET Sites. HS guarantees that during the Term, HS shall provide the following promotion in the following HS Properties in
accordance with the following schedule: 

[*]

	2.
	Changes and Cancellations. Unless otherwise agreed upon by the parties in writing, the Advertising Content must submitted to HET at
least fifteen (15) days prior to the artwork deadline for planned publication date and accepted by HET three (3) days in advance of the printing or broadcast date. Any cancellations or
change orders must be made in writing to the other party.

	3.
	Additional Terms Regarding Internet Advertising. In the event that multiple impressions described in Attachment
A Section 1, appear on a single page of a HS Properties that is a Web Site, only one impression will be counted toward the HS impression guarantees set forth
herein. 

9

 
ATTACHMENT A-1

ADVERTISING CONTENT  

        1.    HS CONTENT: HS shall provide the following artwork for use in connection with the promotion services provided under this
Agreement, subject to HET's prior approval: 

	HS CONTENT
 
	 	DUE DATE
	 	DESCRIPTION

	

 	
 	

 	
 	

 
	

 	
 	

 	
 	

 

        2.    HET Content: HET shall provide the following artwork for use in connection with the promotion services provided under this
Agreement: 

	HET Content
 
	 	DUE DATE
	 	DESCRIPTION

	

 	
 	

 	
 	

 
	

 	
 	

 	
 	

 

        HET
Content also includes any other advertising materials relating to the HET Business and originating with HET and provided to HS pursuant to this Agreement. 

This
Attachment A-1 shall be amended and supplemented by the Parties upon mutual agreement. 

10

 

*    Portions
denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

ATTACHMENT A-2

HEALTHSOUTH SCHEDULE 

[*]

11

   ATTACHMENT B

[FORM]

Warrant  

THIS WARRANT HAS BEEN AND THE SHARES OF COMMON STOCK WHICH MAY BE PURCHASED PURSUANT TO THE EXERCISE OF THE RIGHTS UNDER THIS WARRANT HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT FOR DISTRIBUTION, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT THERETO UNDER SUCH ACT UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT OR UNLESS SUCH SALE, OFFER, PLEDGE, HYPOTHECATION OR
TRANSFER IS OTHERWISE EXEMPT FROM REGISTRATION. THE COMPANY MAY REQUEST A WRITTEN OPINION OF COUNSEL (FROM COUNSEL REASONABLY ACCEPTABLE TO THE COMPANY) SATISFACTORY TO THE COMPANY, TO THE
EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH SALE, OFFER, PLEDGE, HYPOTHECATION OR OTHER TRANSFER. THIS WARRANT OR ANY CERTIFICATE FOR SUCH SECURITIES MUST BE SURRENDERED TO THE
COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, PLEDGE, HYPOTHECATION OR ANY OTHER TRANSFER OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY OR THEREBY.  

 WARRANT TO PURCHASE SHARES OF COMMON STOCK

of

HEALTHETECH, INC.

Dated as of [                ], 2002

Void after November 30, 2003  

	No. [            ]	 	Warrant to Purchase

[1,456,907] Shares of

Common Stock

(subject to adjustment)

        THIS
CERTIFIES THAT, for value received, HealthSouth Corporation, a Delaware corporation (the "Holder"), is entitled, subject to the terms
and conditions set forth below, to purchase from HealtheTech, Inc., a Delaware corporation (the "Company"), shares of the Company's Common Stock,
$0.001 par value per share (the "Shares"), in the amounts, at such times and at the price per share set forth in  Section 1 below, subject to the
provisions and upon the terms and conditions set forth herein. The term
"Warrant" as used herein shall include this Warrant and any warrants delivered in substitution or exchange therefor as provided herein. This Warrant is
issued in consideration for certain advertising, media exposure, printing, video production and other services rendered by the Holder as a strategic partner to the Company in connection with a joint
venture and partnering transaction. 

        1.    Number and Price of Shares.

        (a)  Number of Shares. [note: The dates referenced in this Section 1(a) are based on the assumption that
HealtheTech's IPO closes in June 2002. The exercise periods will be adjusted accordingly if the IPO is delayed and the closing occurs in a subsequent month.] 

        (i)    On
and from August 1, 2002 to and including August 31, 2002, the Holder shall have the right to purchase up to a total of
[            ] Shares [note: This amount will equal 20.0% of the aggregate number of shares subject to this warrant (which will equal 10%
of the total number of shares of Common Stock outstanding immediately prior to the closing of the initial public offering  

12

 

 as set forth in Section 4.1 of the Promotion Agreement)] (as may be adjusted pursuant hereto) (the "August 2002
Shares"). Holder's right to purchase the August 2002 Shares shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on August 31, 2002. 

        (ii)  On
and from November 1, 2002 to and including November 30, 2002, the Holder shall have the right to purchase up to a total of
[            ] Shares [note: This amount will equal 20.0% of the aggregate number of shares subject to this
warrant] (as may be adjusted pursuant hereto) (the "November 2002 Shares"). Holder's right to purchase the
November 2002 Shares shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on November 30, 2002. 

        (iii)  On
and from February 1, 2003 to and including February 28, 2003, the Holder shall have the right to purchase up to a total of
[            ] Shares [note: This amount will equal 20.0% of the aggregate number of shares subject to this
warrant] (as may be adjusted pursuant hereto) (the "February 2003 Shares"). Holder's right to purchase the
February 2003 Shares shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on February 28, 2003. 

        (iv)  On
and from May 1, 2003 to and including May 31, 2003, the Holder shall have the right to purchase up to a total of
[            ] Shares [note: This amount will equal 20.0% of the aggregate number of shares subject to this
warrant] (as may be adjusted pursuant hereto) (the "May 2003 Shares"). Holder's right to purchase the
May 2003 Shares shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on May 31, 2003. 

        (v)  On
and from August 1, 2003 to and including August 31, 2003, the Holder shall have the right to purchase up to a total of
[            ] Shares [note: This amount will equal 10.0% of the aggregate number of shares subject to this
warrant] (as may be adjusted pursuant hereto) (the "August 2003 Shares"). Holder's right to purchase the
August 2003 Shares shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on August 31, 2003. 

        (vi)  On
and from November 1, 2003 to and including November 30, 2003, the Holder shall have the right to purchase up to a total of
[            ] Shares [note: This amount will equal 10.0% of the aggregate number of shares subject to this
warrant] (as may be adjusted pursuant hereto) (the "November 2003 Shares"). Holder's right to purchase the
November 2003 Shares shall terminate, to the extent not exercised, at 5:00 p.m., Mountain Time, on November 30, 2003. 

        (b)  Exercise Price. The exercise price per Share shall be equal to $[            ] per Share
[note: This amount will equal the IPO price], as adjusted from time to time pursuant to Section 8 hereof (the "Exercise
Price"). 

        2.    Exercise Of Warrants.

        (a)  Exercise. The purchase rights represented by this Warrant may be exercised at the election of the Holder, in whole or in
part, but not for less than five thousand (5,000) Shares at a time (or such lesser number of shares which may then constitute the maximum number purchasable pursuant to Section 1) (such number
being subject to adjustment as provided in Section 8 hereof), in accordance with Section 1 and prior to the expiration of this Warrant as set forth in Section 10, by
(i) the tender to the Company at its principal office (or such other office or agency of the Company as it may designate by notice in writing to the Holder at the address of the Holder
appearing on the books of the Company) of a notice of exercise in the form attached hereto as Exhibit B-1 (the
"Notice of Exercise"), duly completed and executed on behalf of the Holder, together with the surrender of this Warrant, and (ii) the payment to
the Company of an amount equal to the Exercise Price multiplied by the number of Shares being purchased by wire transfer or certified, cashier's or other check acceptable to the Company and payable to
the order of the Company. 

13

 

        (b)  Stock Certificates. The rights under this Warrant shall be deemed to have been exercised and the Shares shall be deemed
to have been issued immediately prior to the close of business on the date of its tender for exercise as provided above, and the person entitled to receive the Shares issuable upon such exercise shall
be treated for all purposes as the holder of record of such Shares as of the close of business on such date. As promptly as reasonably practicable on or after such date, the Company shall issue and
deliver to the person or persons entitled to receive the same a certificate or certificates for that number of shares issuable upon such exercise. In the event that the rights under this Warrant are
exercised in part and have not expired, the Company shall execute and deliver a new Warrant with the same terms and conditions for the number of Shares that remain subject to this Warrant. 

        (c)  Taxes. In no event shall the Company be required to pay any tax which may be payable in respect of any transfer involved
in the issue and delivery of any certificate in a name other than that of the Holder, and the Company shall not be required to issue or deliver any such certificate unless and until the person or
persons requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid. 

        3.    No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of the rights under this Warrant. In lieu of such fractional share to which the Holder would otherwise be entitled, the Company shall make a cash payment equal to the Exercise Price
multiplied by such fraction. 

        4.    Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and substance to the Company or, in the case of
mutilation, on surrender and cancellation of this Warrant, the Company at the expense of the Holder shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount. 

        5.    Representations and Warranties of the Holder.

        (a)  No Registration. The Holder understands that this Warrant and the Shares issuable upon exercise of the rights under this
Warrant (the "Securities") have not been, and will not be, registered under the Securities Act of 1933, as amended (the
"Securities Act") by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon,
among other things, the bona fide nature of the investment intent and the accuracy of the Holder's representations as expressed herein or otherwise made pursuant hereto. 

        (b)  Investment Intent. The Holder is acquiring the Securities for investment for its own account, not as a nominee or agent,
and not with the view to, or for resale in connection with, any distribution thereof. 

        (c)  Investment Experience. The Holder has substantial experience in evaluating and investing in private placement
transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own
interests. 

        (d)  Speculative Nature of Investment. The Holder acknowledges that its investment in the Company is highly speculative and
entails a substantial degree of risk and the Holder is in a position to lose the entire amount of such investment. 

        (e)  Access to Data. The Holder has had an opportunity to discuss the Company's business, management and financial affairs
with the Company's management. The Holder has also had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Holder understands that such
discussions, as well as any information issued by the 

14

 

Company, were intended to describe certain aspects of the Company's business and prospects, but were not necessarily a thorough or exhaustive description. The Holder acknowledges that any business
plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can
be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual results. 

        (f)    Accredited Investor. The Holder is an "accredited investor" within the meaning of Regulation D,
Rule 501(a), promulgated by the Securities and Exchange Commission. 

        (g)  Residency. The residency of the Holder (or, in the case of a partnership or corporation, such entity's principal place of
business) is correctly set forth on the signature page hereto. 

        (h)  Restriction on Resales. The Holder acknowledges that the Securities must be held indefinitely unless subsequently
registered under the Securities Act or unless an exemption from such registration is available. The Company has no present intention of registering such Securities. The Holder further understands that
there is no assurance that any exemption from registration under the Securities Act will be available or, if available, that such exemption will allow the Holder to dispose of or otherwise transfer
any or all of the Securities under the circumstances, in the amounts or at the times the Holder might propose. 

        (i)    Rule 144. The Holder is aware of the provisions of Rule 144 promulgated under the Securities Act which
permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions, including among other things, the existence of a public market for the shares, the
availability of certain current public information about the Company, the resale occurring not less than one year after a party has purchased and paid for the security to be sold, the sale being
effected through a "broker's transaction" or in transactions directly with a "market maker" and the number of shares being sold during any three-month period not exceeding specified limitations. The
Holder acknowledges that, in the event all of the requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any
disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell
restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from
registration is available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 

        (j)    Authorization.

        (i)    The
Holder has all requisite power and authority to execute and deliver this Warrant, to purchase the Shares issuable upon exercise of the rights under this Warrant and
to carry out and perform its obligations under the terms and conditions of this Warrant. All action on the part of the Holder necessary for the authorization, execution, delivery and performance of
this Warrant, and the performance of all of the Holder's obligations under this Warrant, has been taken or will be taken prior to the purchase of this Warrant. 

        (ii)  This
Warrant, when executed and delivered by the Holder, will constitute a valid and legally binding obligation of the Holder, enforceable in accordance with its terms
except: (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of equity. 

        (iii)  No
consent, approval, authorization, order, filing, registration or qualification of or with any court, governmental authority or third person is required to be
obtained by the 

15

 

Holder in connection with the execution and delivery of this Warrant or the performance of the Holder's obligations hereunder. 

        (k)  Brokers and Finders. The Holder has not engaged any brokers, finders or agents in connection with this Warrant, and the
Company has not incurred and will not incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders' fees or agents' commissions or any similar
charges in connection with this Warrant. 

        (l)    Investor Counsel. The Holder acknowledges that it has had the opportunity to review this Warrant, the exhibits and
schedules attached thereto and the transactions contemplated by this Warrant with its own legal counsel. The Holder is relying solely on such counsel and not on any statements or representations of
the Company or its agents for legal advice with respect to this investment or the transactions contemplated by this Warrant. 

        (m)  Tax Advisors. The Holder has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax
consequences of this investment and the transactions contemplated by this Warrant. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations
of the Company or any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment
or the transactions contemplated by this Warrant. 

        6.    Transfer of Warrants; Restrictions on Transfer.

        (a)  Warrant Register. The Company shall maintain a register (the "Warrant
Register") containing the name and address of the Holder or Holders. Any Holder of this Warrant or any portion thereof may change its address as shown on the Warrant Register
by written notice to the Company requesting such change. Any written notice or written communication required or permitted to be given to the Holder may be delivered or given by any method provided in
Section 11(d) hereof. Until this Warrant is transferred on the Warrant Register, the Company may treat the Holder as shown on the Warrant Register as the absolute owner of this Warrant
for all purposes, notwithstanding any notice to the contrary. 

        (b)  Warrant Agent. The Company may, by notice to the Holder, appoint an agent for the purpose of maintaining the Warrant
Register referred to in Section 6(a) above, issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant, exchanging this Warrant, replacing
this Warrant or any or all of the foregoing. Thereafter, any such registration, issuance, exchange or replacement, as the case may be, shall be made at the office of such agent. 

        (c)  Transferability and Non-negotiability of Warrant. This Warrant may not be transferred or assigned in whole or
in part without compliance with all applicable federal and state securities laws by the transferor and the transferee. Subject to the provisions of this Warrant with respect to compliance with the
Securities Act and limitations on assignments and transfers, including without limitation compliance with the restrictions on transfer set forth in Section 6(e) hereof, title to this
Warrant may be transferred by endorsement (by the transferor and the transferee executing the assignment form (the "Assignment Form") attached hereto as  Exhibit B-3) and delivery in the same manner as a negotiable instrument transferable by endorsement and delivery. 

        (d)  Exchange of Warrant Upon a Transfer. On surrender of this Warrant for exchange and a properly endorsed Assignment Form,
and subject to the provisions of this Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers, the Company shall issue to or on the order of the Holder
a new warrant or warrants with the same terms and conditions, in the name of the Holder or as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of
shares issuable upon exercise of the rights hereunder and the Company shall register any such transfer upon the Warrant Register. This Warrant and the Shares issuable upon exercise of the rights under
this Warrant must be 

16

 

surrendered to the Company or its warrant or transfer agent, as applicable, as a condition precedent to the sale, pledge, hypothecation or any other transfer of any interest in any of the securities
represented hereby. 

        (e)  Restrictions on Transfer of Warrants and Shares; Compliance with Securities Laws.

        (i)    The
Holder agrees not to make any disposition of all or any portion of the Shares or this Warrant unless and until, and it shall be a condition to the transfer of all or
any portion of the Shares or this Warrant that: (1) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in
accordance with such registration statement or (2) (A) the Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, (B) the transferee shall have agreed in writing to be bound by and subject to the terms, conditions, restrictions,
obligations and other limitations set forth in this Warrant to the same extent as if such transferee were the original Holder hereunder, (C) the transferee shall have confirmed to the
satisfaction of the Company in writing, substantially in the form attached hereto as Exhibit B-2, that the Shares or the Warrant
purchased are being acquired solely for the transferee's own account and not as a nominee for any other party, for investment and not with a view toward distribution or resale and that the transferee
shall have confirmed such other matters related thereto as may be reasonably requested by the Company, and (D) if requested by the Company, the Holder shall have furnished the Company with an
opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of the Warrant or such Shares under the Securities Act. This Warrant or any portion
hereof and any Shares issuable pursuant to the exercise of the rights under this Warrant that are transferred to a transferee shall be subject to the terms, conditions, restrictions, obligations and
other limitations set forth herein. 

        (ii)  Unless
the rights under this Warrant are exercised pursuant to an effective registration statement under the Securities Act that includes the Shares with respect to
which the Warrant was exercised, it shall be a condition to any exercise of the rights under this Warrant that the Holder shall have confirmed to the satisfaction of the Company in writing,
substantially in the form attached hereto as Exhibit B-2, that the Shares so purchased are being acquired solely for the Holder's own
account and not as a nominee for any other party, for investment and not with a view toward distribution or resale and
that the Holder shall have confirmed such other matters related thereto as may be reasonably requested by the Company. 

        (iii)  This
Warrant and all Shares issued upon exercise hereof shall be stamped or imprinted with a legend in substantially the following form (in addition to any legend
required by state securities laws): 

17

  

        THE
SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION THEREOF. SUCH SECURITIES AND THE
SECURITIES ISSUED HEREUNDER AND THEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, OFFERED, PLEDGED,
HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH DISPOSITION IS EXEMPT FROM THE
REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THE WARRANT AGREEMENT OR ANY CERTIFICATE FOR SUCH SECURITIES MUST BE SURRENDERED TO THE COMPANY
OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, PLEDGE, HYPOTHECATION OR ANY OTHER TRANSFER OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY OR THEREBY. 

        (iv)  The
Holder of this Warrant, by acceptance hereof, hereby agrees not to sell or otherwise transfer or dispose of this Warrant, any Shares or other securities of the
Company held by such person or entity for a period of one hundred eighty (180) days following the effective date of the first registration statement of the Company filed under the Securities
Act, provided, that all officers and directors of the Company and holders of 1% or more of the Company's outstanding shares enter or have entered into similar agreements. The Holder of this Warrant
agrees to execute a market standoff agreement with the managing underwriter of an underwritten public offering by the Company of Common Stock in customary form, including a market standoff agreement
substantially in the form attached as Exhibit B-4. The Company may impose a stop-transfer instruction with respect to
this Warrant, any Shares or other securities of the Company held by such person or entity until the end of the applicable market standoff period. 

        (f)    This
Warrant may not be transferred in part unless such transfer is to a transferee who, pursuant to such transfer, receives the right to purchase at least five thousand
(5,000) Shares hereunder (as adjusted from time to time in accordance with Section 8 hereof). 

        7.    Reservation of Stock. The Company agrees during the term the rights under this Warrant are exercisable to reserve from its
authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Shares upon the exercise of the rights under this Warrant and, from time to time, to use its best
efforts to amend its Certificate of Incorporation to provide sufficient reserves of shares of Common Stock issuable upon exercise of the rights under the Warrant. 

        8.    Adjustment Rights. The number and kind of shares purchasable hereunder and the Exercise Price therefor are subject to
adjustment from time to time, as follows: 

        (a)  Merger. If at any time there shall be any reorganization, recapitalization, merger or consolidation involving the Company
in which shares of the Company's stock (other than a reorganization, recapitalization, merger or consolidation or a related combination, reclassification, exchange, capital reorganization, subdivision
of securities or other transaction otherwise provided for herein) are converted into or exchanged for securities, cash or other property, other than as would cause the expiration of this Warrant under
Section 10 hereof, then, as a part of such reorganization, recapitalization, merger or consolidation, lawful provision shall be made so that the Holder shall thereafter be entitled to receive
upon exercise of its rights to purchase the Shares hereunder, the kind and amount of securities, cash or other property of the successor corporation resulting from such reorganization,
recapitalization, merger or consolidation, equivalent in value to that which a holder of the Common Stock deliverable upon exercise of such rights to purchase the 

18

 

Shares hereunder would have been entitled in such reorganization, recapitalization, merger or consolidation if such rights to purchase the Shares hereunder had been exercised immediately prior to
such reorganization, recapitalization, merger or consolidation. In any such case, appropriate adjustment (as determined in good faith by the Company's Board of Directors) shall be made in the
application of the provisions of this Warrant with respect to the rights and interests of the Holder after such reorganization, recapitalization, merger or consolidation to the end that the provisions
of this Warrant (including adjustments of the Exercise Price and number of shares of Common Stock purchasable pursuant to the terms and conditions of this Warrant) shall be applicable after the event,
as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of the Holder's rights to purchase the Shares pursuant to this Warrant. 

        (b)  Reclassification of Shares. If the Company at any time shall, by combination, reclassification, exchange, capital
reorganization or subdivision of securities or otherwise (other than a combination, reclassification, exchange, capital reorganization or subdivision of securities or a related reorganization,
recapitalization, merger, consolidation or other transaction otherwise provided for herein), change any of the securities as to which purchase rights under this Warrant exist into the same or a
different number of securities of any other class or classes, this Warrant shall thereafter provide for the right or rights to acquire such number and kind of securities as would have been issuable as
the result of such change with respect to the securities which were subject to the purchase rights under this Warrant immediately prior to such combination, reclassification, exchange, capital
reorganization, subdivision or other change. In any such case, appropriate adjustment (as determined in good faith by the Company's Board of Directors) shall be made in the application of the
provisions of this Warrant with respect to the rights and interests of the Holder after such combination, reclassification, capital reorganization, exchange, subdivision or change to the end that the
provisions of this Warrant (including adjustments of the Exercise Price and number of shares of Common Stock purchasable pursuant to the terms and conditions of this Warrant) shall be applicable after
the event, as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of the Holder's rights to purchase the Shares pursuant to this
Warrant. 

        (c)  Subdivisions and Combinations. In the event that the Company shall at any time subdivide (by stock split, by payment of a
stock dividend or otherwise) the outstanding shares of Common Stock, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such subdivision shall,
concurrently with the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased, and in the event that the Company shall at any time
combine (by reclassification or otherwise) the outstanding shares of Common Stock into a lesser number of shares of Common Stock, the number of Shares issuable upon exercise of the rights under this
Warrant immediately prior to such combination shall, concurrently with the effectiveness of such combination, be proportionately decreased, and the Exercise Price shall be proportionately increased. 

        (d)  Notice of Adjustments. Upon any adjustment of the Exercise Price or any increase or decrease in the number of Shares
purchasable upon the exercise of the rights under this Warrant in accordance with this Section 8, then, and in each such case, the Company, within thirty (30) days thereafter, shall give
notice thereof, to the Holder at the address of such Holder as shown on the Warrant Register of the Company, delivered by any method provided in Section 11(d) hereof, which notice shall
state the event giving rise to the adjustment, the Exercise Price as adjusted and, if applicable, the increased or decreased number of Shares purchasable upon the exercise of the rights under this
Warrant, setting forth in reasonable detail the method of calculation of each. 

19

 

        (e)  Other Notices. In the event that the Company shall authorize: (1) the issuance of any dividend or other
distribution on the Common Stock (other than: (i) repurchases of Common Stock issued to or held by employees, officers, directors or consultants of the Company or its subsidiaries upon
termination of their employment or services pursuant to agreements providing for the right of said repurchase; (ii) repurchases of Common Stock issued to or held by employees, officers,
directors or consultants of the Company or its subsidiaries pursuant to rights of first refusal contained in agreements providing for such right; or (iii) repurchases of capital stock of the
Company in connection with the settlement of disputes with any stockholder), whether in cash, property, stock or other securities; (2) the voluntary liquidation, dissolution or winding up of
the Company; or (3) any transaction resulting in the expiration of this Warrant pursuant to Section 10(b) hereof; then, in each such case, the Company shall give written notice
thereof to the Holder at the address of such Holder as shown on the Warrant Register of the Company, delivered by any method provided in Section 11(d) hereof, at least five
(5) days prior to the effective date of such event. The notice provisions set forth in this section may be shortened or waived prospectively or retrospectively by the vote or written
consent of the holders of a majority of the Shares issuable upon exercise of the rights under this Warrant. 

        9.    No Rights As Stockholder. Nothing contained herein shall entitle the Holder to any rights as a stockholder of the Company
or to be deemed the holder of Common Stock or any other securities that may at any time be issuable on the exercise of the rights hereunder for any purpose nor shall anything contained herein be
construed to confer upon the Holder, as such, any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any
corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value or change of stock to no par value, consolidation, merger, conveyance or
otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise
or any other rights of a stockholder of the Company until the rights under the Warrant shall have been exercised and the Shares purchasable upon exercise of the rights hereunder shall have become
deliverable as provided herein. 

        10.  Expiration of Warrant. This Warrant shall expire and shall no longer be exercisable as of 5:00 p.m., Mountain
Time, on November 30, 2003. 

        11.  Miscellaneous.

        (a)  Effective Date. The provisions of this Warrant shall be construed and shall be given effect in all respects as if it had
been executed and delivered by the Company on the date hereof. 

        (b)  Waiver and Amendment. Any provision of this Warrant may be amended, waived or modified only upon the written consent of
the Company and the Holder. 

        (c)  Successors and Assigns. Except as provided in Section 6, this Warrant, and any and all rights, duties and
obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by any party hereto without the prior written consent of the other party. Any attempt by a party without such
permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Warrant shall be void. Subject to the foregoing and except as otherwise provided herein,
the provisions of this Warrant shall inure to the benefit of, and be binding upon, the successors and assigns of the parties. 

        (d)  Notices. All notices and other communications provided for hereunder shall be in writing and delivered, mailed or
telecopied. Notices and other communications to the Holder shall be directed to it at the respective addresses of the Holder or Holders as shown on the Warrant Register maintained by the Company; and
notices and other communications to the Company shall be directed to it at its address as shown on the signature page hereto (any notice or other communication sent to the Company should be
directed to the attention of the President or Chief 

20

 

Financial Officer of the Company); or, as to each party, at such other address as shall be designated by such party in a written notice to the other party pursuant hereto. Any such notice or other
communication shall be deemed to have been duly given (i) when sent by Federal Express or other overnight delivery service of recognized standing, on the business day following deposit with
such service; (ii) when mailed by registered or certified mail, first class postage prepaid and addressed as aforesaid through the United States Postal Service, upon receipt; (iii) when
delivered by hand, upon delivery; and (iv) when telecopied, upon confirmation of receipt. Any party hereto may by notice so given change its address for future notice hereunder. 

        (e)  Governing Law. This Warrant and all actions arising out of or in connection with this Warrant shall be governed by and
construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware, or of any other state. 

        (f)    California Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN
QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH
QUALIFICATION IS UNLAWFUL UNLESS THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT
ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT. 

        (g)  Further Assurances. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited
liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be reasonably necessary to more fully effectuate
this Warrant. 

        (h)  Entire Agreement. Except as expressly set forth herein, this Warrant (including the exhibits attached hereto) constitutes
the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. 

        (i)    WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AND ANY ACTION,
PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS WARRANT OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR
ENFORCEMENT HEREOF. 

        (j)    Counterparts. This Warrant may be executed in one or more counterparts, all of which shall be considered one and the same
agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that all parties need not sign the same
counterpart. 

        (k)  Titles and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be
considered in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs
hereof and exhibits attached hereto. 

21

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed as of the date first above written. 

	

 	
 	
HEALTHETECH, INC.
	

 	
 	

By:	
 	

 
	 	 	 	 	

	 	 	 	 	Name:

Title:

Address: 523 Park Point Drive, 3rd Floor

Golden, Colorado 80401

	
AGREED TO AND ACKNOWLEDGED BY THE HOLDER:	
 	

 
	

Healthsouth corporation	
 	

 
	 	 	 	 	 
	By:	 	 	 	 
	 	 	
	 	 
	Name:

Title:

Address: One HealthSouth Parkway,

Birmingham, Alabama 34243	 	 

(Signature Page to Warrant to Purchase Shares of Common Stock of HealtheTech, Inc.)  

22

 
EXHIBIT B-1

NOTICE OF EXERCISE  

	TO:	 	HEALTHETECH, INC.
	Attention:	 	President

        (1)  The
undersigned Holder hereby elects to purchase            shares of the Common Stock of HEALTHETECH, INC., pursuant to the terms of the attached Warrant to
Purchase Shares of Common Stock, dated as of [            ], 2002 (the "Warrant"), between HEALTHETECH, INC. and the
Holder, and tenders herewith payment of the purchase price for such shares in full, together with all applicable transfer taxes, if any. 

        (2)  Please
issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below: 

	 	 	
 Name
	 	 	 
	 	 	
 Address

        (3)  Please
issue a new Warrant for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as is specified below: 

	 	 	
 Name
	 	 	 
	 	 	
 Address

        (4)  The
undersigned hereby represents and warrants that the aforesaid shares of Common Stock are being acquired for investment, solely for the account of the undersigned and
not as a nominee for any other person and not with a view to, or for resale in connection with, the distribution thereof, and that the undersigned has no present intention of distributing or reselling
such shares except under circumstances that will not result in a violation of the Securities Act of 1933, as amended, or any applicable state securities laws, and all representations and warranties of
the undersigned set forth in Section 5 and Section 6(e) of the attached Warrant are
true and correct as of the date hereof. In support thereof, the undersigned agrees to execute an Investment Representation Statement in a form substantially similar to the form attached to the Warrant
as Exhibit B-2. 

(The remainder of this page is intentionally left blank.)  

23

 

	

Date	
 	

 Signature
	

 	
 	

 Name
	

 	
 	

 Title and Name of Entity (if signing on behalf of an entity)

(Signature Page to the Notice of Exercise)  

24

   EXHIBIT B-2

INVESTMENT REPRESENTATION STATEMENT  

	HOLDER:	 	 
	COMPANY:	 	HEALTHETECH, INC.
	SECURITIES:	 	THE WARRANT (THE "WARRANT") TO PURCHASE SHARES OF COMMON STOCK ISSUED ON
[                        ], 2002 AND THE COMMON STOCK ISSUED OR ISSUABLE UPON EXERCISE THEREOF
	AMOUNT:	 	                        SHARES
	DATE:	 	                        ,
            

        In
connection with the purchase of the above-listed Securities, the undersigned Holder represents and warrants to, and agrees with, the Company as follows: 

        1.    No Registration. The Holder understands that the Securities have not been, and will not be, registered under the
Securities Act of 1933, as amended (the "Securities Act"), by reason of a specific exemption from the registration provisions of the Securities Act, the
availability of which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Holder's representations as expressed herein or otherwise made pursuant
hereto. 

        2.    Investment Intent. The Holder is acquiring the Securities for investment for its own account, not as a nominee or agent,
and not with the view to, or for resale in connection with, any distribution thereof. 

        3.    Investment Experience. The Holder has substantial experience in evaluating and investing in private placement transactions
of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. 

        4.    Speculative Nature of Investment. The Holder acknowledges that its investment in the Company is highly speculative and
entails a substantial degree of risk and the Holder is in a position to lose the entire amount of such investment. 

        5.    Access to Data. The Holder has had an opportunity to discuss the Company's business, management and financial affairs with
the Company's management. The Holder has also had an opportunity to ask questions of officers of the Company, which questions were answered to its satisfaction. The Holder understands that such
discussions, as well as any information issued by the Company, were intended to describe certain aspects of the Company's business and prospects, but were not necessarily a thorough or exhaustive
description. The Holder acknowledges that any business plans prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or
otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the projections will not materialize or will vary significantly from actual
results. 

        6.    Accredited Investor. The Holder is an "accredited investor" within the meaning of Regulation D, Rule 501(a),
promulgated by the Securities and Exchange Commission. 

        7.    Residency. The residency of the Holder (or, in the case of a partnership or corporation, such entity's principal place of
business) is correctly set forth on the signature page hereto. 

        8.    Restriction on Resales. The Holder acknowledges that the Securities must be held indefinitely unless subsequently
registered under the Securities Act or unless an exemption from such registration is available. The Company has no present intention of registering the Securities. The Holder further understands that
there is no assurance that any exemption from registration under the Securities Act will be available or, if available, that such exemption will allow the Holder to dispose of or otherwise 

25

 

transfer any or all of the Securities under the circumstances, in the amounts or at the times the Holder might propose. 

        9.    Rule 144. The Holder is aware of the provisions of Rule 144 promulgated under the Securities Act which
permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions, including among other things, the existence of a public market for the shares, the
availability of certain current public information about the Company, the resale occurring not less than one year after a party has purchased and paid for the security to be sold, the sale being
effected through a "broker's transaction" or in transactions directly with a "market maker" and the number of shares being sold during any three-month period not exceeding specified limitations. The
Holder acknowledges that, in the event all of the requirements of Rule 144 are not met, registration under the Securities Act or an exemption from registration will be required for any
disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its opinion that persons proposing to sell
restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from
registration is available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 

        10.  Authorization. (a) The Holder has all requisite power and authority to execute and deliver the Warrant, to
purchase the Securities and to carry out and perform its obligations under the terms of the Warrant. All action on the part of the Holder necessary for the authorization, execution, delivery and
performance of the Warrant, and the performance of all of the Holder's obligations under the Warrant, has been taken or will be taken prior to the purchase of the Warrant. 

        (b)  The
Warrant, when executed and delivered by the Holder, will constitute a valid and legally binding obligation of the Holder, enforceable in accordance with its terms
except: (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights generally, and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies or by general principles of equity. 

        (c)  No
consent, approval, authorization, order, filing, registration or qualification of or with any court, governmental authority or third person is required to be obtained
by the Holder in connection with the execution and delivery of the Warrant or the performance of the Holder's obligations hereunder. 

        11.  Brokers or Finders. The Holder has not engaged any brokers, finders or agents, and the Company has not incurred and will
not incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders' fees or agents' commissions or any similar charges in connection with the
Warrant. 

        12.  Investor Counsel. The Holder acknowledges that it has had the opportunity to review the Warrant, the exhibits and
schedules attached thereto and the transactions contemplated by the Warrant with its own legal counsel. The Holder is relying solely on such counsel and not on any statements or representations of the
Company or its agents for legal advice with respect to this investment or the transactions contemplated by the Warrant. 

        13.  Tax Advisors. The Holder has reviewed with its own tax advisors the U.S. federal, state, local and foreign tax
consequences of this investment and the transactions contemplated by the Warrant. With respect to such matters, the Holder relies solely on such advisors and not on any statements or representations
of the Company or any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of this investment
or the transactions contemplated by the Warrant. 

26

 

        14.  Further Limitations on Disposition. Without in any way limiting the representations and warranties set forth above, the
Holder agrees not to make any disposition of all or any portion of the Securities unless and until, and it shall be a condition to the transfer of all or any portion of the Securities that:
(1) there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement or
(2) (A) the Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the
proposed disposition, (B) the transferee shall have agreed in writing to be bound by and subject to the terms, conditions, restrictions, obligations and other limitations set forth in the
Warrant to the same extent as if such transferee were the original Holder thereunder, (C) the transferee shall have confirmed to the satisfaction of the Company in writing, substantially in the
form attached to the Warrant as Exhibit B-2, that the Securities are being acquired solely for the transferee's own account and not
as a nominee for any other party, for investment and not with a view toward distribution or resale and that the transferee shall have confirmed such other matters related thereto as may be reasonably
requested by the Company, and (D) if requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such
disposition will not require registration of the Securities under the Securities Act. The Securities that are transferred to a transferee shall be subject to the terms, conditions, restrictions,
obligations and other limitations set forth herein and therein. 

        15.  Market Standoff. The Holder agrees not to sell or otherwise transfer or dispose of any Securities or other securities of
the Company held by such person or entity for a period of one hundred eighty (180) days following the effective date of the first registration statement of the Company filed under the
Securities Act, provided, that all officers and directors of the Company and holders of 1% or more of the Company's outstanding shares enter or have
entered into similar agreements. The Holder agrees to execute a market standoff agreement with the managing underwriter of an underwritten public offering by the Company of Common Stock in customary
form, including a market standoff agreement substantially in the form attached as Exhibit B-4 to the Warrant. The Company may impose
a stop-transfer instruction with respect to the Securities or other securities of the Company held by such person or entity until the end of the applicable market standoff period. 

(The remainder of this page is intentionally left blank.)  

27

 

        IN WITNESS WHEREOF, the Holder has caused this Investment Representation Statement to be duly executed and delivered by its proper and duly authorized officers as
of the date and year first written above. 

	

 	
 	
HOLDER:
	

 	
 	

By:	
 	

	

 	
 	

Name:	
 	

	

 	
 	

Title:	
 	

	

 	
 	

Address:	
 	

	

 	
 	

 	
 	

	

 	
 	

 	
 	

(Signature page to the Investment Representation Statement)  

28

   EXHIBIT B-3

ASSIGNMENT FORM  

	ASSIGNOR:	 	 
	COMPANY:	 	HEALTHETECH, INC.
	WARRANT:	 	THE WARRANT (THE "WARRANT") TO PURCHASE SHARES OF COMMON STOCK ISSUED ON [            ], 2002
	DATE:	 	                        ,
            

        FOR
VALUE RECEIVED, the undersigned registered Holder of the Warrant ("Assignor") hereby sells, assigns and transfers unto the Assignee
named below all of the rights of the undersigned under the within Warrant, with respect to the number of shares of Common Stock set forth below: 

	Name of Assignee
 
	 	Address
	 	Number of Shares
	 	Exercise Period

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

and
does irrevocably constitute and appoint                        as attorney to make such transfer on the books of HEALTHETECH,
 INC., maintained for the purpose, with full power of substitution in
the premises. 

        Each
of the Assignor and Assignee also represent and warrant that, by assignment hereof, the Assignee acknowledges that the Warrant and the shares of stock to be issued upon exercise of
the rights thereunder are being acquired for investment and that the Assignee will not offer, sell or otherwise dispose of the Warrant or any shares of stock to be issued upon exercise of the rights
thereunder except under circumstances which will not result in a violation of the Securities Act of 1933, as amended, or any state securities laws. Further, the Assignee has acknowledged that upon
exercise of any rights under the Warrant, the Assignee shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the shares of stock so purchased are being
acquired for investment and not with a view toward distribution or resale. In support thereof, the undersigned Assignee agrees to execute an Investment Representation Statement in a form substantially
similar to the form attached to the Warrant as Exhibit B-2 in connection with this assignment and any exercise of the rights under
the Warrant. 

	
ASSIGNOR:	
 	

ASSIGNEE:
	

By:	
 	

	
 	

By:	
 	

	 	 	Name:	 	 	 	Name:
	 	 	Title:	 	 	 	Title:
	 	 	 	 	 	 	 
	 	 	Address:	 	 	 	Address:
	

 	
 	

	
 	

 	
 	

	

 	
 	

	
 	

 	
 	

	

 	
 	

	
 	

 	
 	

(Signature page to the Assignment Form)  

29

 
EXHIBIT B-4

FORM OF MARKET STANDOFF AGREEMENT  

March 15,
2002 

HealtheTech, Inc.

523 Park Point Drive, 3d Floor

Golden, CO 80401 

Credit
Suisse First Boston Corporation

UBS Warburg

William Blair & Company, LLC

Stifel, Nicolaus & Company, Incorporated 

c/o
Credit Suisse First Boston Corporation

Eleven Madison Avenue

New York, NY 10010-3629 

Dear
Sirs: 

        As
an inducement to the Underwriters to execute the Underwriting Agreement, pursuant to which an offering will be made that is intended to result in the establishment of a public market
for the common stock, par value $.001 per share (the "Securities"), of HealtheTech, Inc., and any successor (by merger or otherwise) thereto,
(the "Company"), the undersigned hereby agrees that from the date hereof and until 180 days after the public offering date set forth on the final
prospectus used to sell the Securities (the "Public Offering Date") pursuant to the Underwriting Agreement, to which you are or expect to become
parties, the undersigned will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of Securities or securities convertible into or exchangeable or
exercisable for any shares of Securities, enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the
economic consequences of ownership of the Securities, whether any such aforementioned transaction is to be settled by delivery of the Securities or such other securities, in cash or otherwise, or
publicly disclose the intention to make any such offer, sale, pledge or disposition, or to enter into any such transaction, swap, hedge or other arrangement, without, in each case, the prior written
consent of Credit Suisse First Boston Corporation. In addition, the undersigned agrees that, without the prior written consent of Credit Suisse First Boston Corporation, it will not, during the period
commencing on the date hereof and ending 180 days after the Public Offering Date, make any demand for or exercise any right with respect to, the registration of any Securities or any security
convertible into or exercisable or exchangeable for the Securities. 

        Any
Securities received upon exercise of options granted to the undersigned will also be subject to this Agreement. Any Securities acquired by the undersigned in the open market or in
the issuer directed share program will not be subject to this Agreement. A transfer of Securities to a family member or trust may be made, provided the transferee agrees in writing to be bound by the
terms of this Agreement prior to such transfer. 

        In
furtherance of the foregoing, the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of Securities if such transfer would
constitute a violation or breach of this Agreement. 

30

 

        This
Agreement shall be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. This Agreement shall lapse and become null and void
if the Public Offering Date shall not have occurred on or before September 30, 2002. 

	Very truly yours,	 	 
	 	 	 
	 	 	 
	

 (Signature)	
 	

 
	

 (Print Name)	
 	

 
	

 (Print title if signing on behalf of an entity)	
 	

 
	

Dated:	
 	

 
	

	
 	

 

31

 
attachment C

HET TRADEMARKS  

	HET Mark
 
	 	Relevant Jurisdiction(s)

	HealtheTech (name and stylized mark)	 	US
	BodyGem	 	US
	Your Body Is Talking. Listen.	 	US
	BalanceLog	 	US
	Calorie Checkbook	 	US
	Listen To Your Body	 	US

32

QuickLinks

EXHIBIT 10.38

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]